###begin article-title 0
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth
###end article-title 0
###begin p 1
###xml 188 189 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 305 313 305 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 327 331 327 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 491 492 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 771 772 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 868 869 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 905 906 903 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1087 1088 1085 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1316 1324 1314 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 165 170 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 185 188 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 204 209 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 225 228 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1006 1011 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1084 1087 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To confirm and refine associations of human leukocyte antigen (HLA) genotypes with variable antibody (Ab) responses to hepatitis B vaccination, we have analyzed 255 HIV-1 seropositive (HIV+) youth and 80 HIV-1 seronegatives (HIV-) enrolled into prospective studies. In univariate analyses that focused on HLA-DRB1, -DQA1, and -DQB1 alleles and haplotypes, the DRB1*03 allele group and DRB1*0701 were negatively associated with the responder phenotype (serum Ab concentration >/= 10 mIU/mL) (P = 0.026 and 0.043, respectively). Collectively, DRB1*03 and DRB1*0701 were found in 42 (53.8%) out of 78 non-responders (serum Ab <10 mIU/mL), 65 (40.6%) out of 160 medium responders (serum Ab 10-1,000 mIU/mL), and 27 (27.8%) out of 97 high responders (serum Ab >1,000 mIU/mL) (P < 0.001 for trend). Meanwhile, DRB1*08 was positively associated with the responder phenotype (P = 0.010), mostly due to DRB1*0804 (P = 0.008). These immunogenetic relationships were all independent of non-genetic factors, including HIV-1 infection status and immunodeficiency. Alternative analyses confined to HIV+ youth or Hispanic youth led to similar findings. In contrast, analyses of more than 80 non-coding, single nucleotide polymorphisms within and beyond the three HLA class II genes revealed no clear associations. Overall, several HLA-DRB1 alleles were major predictors of differential Ab responses to hepatitis B vaccination in youth, suggesting that T-helper cell-dependent pathways mediated through HLA class II antigen presentation are critical to effective immune response to recombinant vaccines.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00439-009-0720-z) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2004</xref>
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2008</xref>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2008</xref>
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2008</xref>
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2007</xref>
###xml 553 557 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1988</xref>
###xml 571 575 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">1992</xref>
###xml 725 729 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2006</xref>
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2009</xref>
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2008</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2005</xref>
###xml 819 823 819 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2006</xref>
###xml 955 959 955 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2009</xref>
###xml 972 976 972 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2000</xref>
###xml 1113 1117 1113 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2008</xref>
###xml 1133 1137 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2003</xref>
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 19 22 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 58 64 <span type="species:ncbi:9606">people</span>
###xml 198 201 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 277 280 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Hepatitis B virus (HBV) infection affects 350-400 million people globally (Custer et al. 2004; Dienstag 2008; Fattovich et al. 2008; Lai and Yuen 2008; McGovern 2007). Vaccines based on recombinant HBV surface antigen (HBsAg) offer a safe and effective strategy for preventing HBV infection, as anti-HBsAg antibody (Ab) concentrations can exceed the minimum protective level of 10 mIU/mL for up to 95% of healthy recipients. Nonetheless, lack of efficacy can be a problem to vaccine recipients with compromised or impaired immune system (Collier et al. 1988; Zuin et al. 1992), which has prompted the search for further improvements through (a) increasing the amount of antigen given in each injection (Cornejo-Juarez et al. 2006; Cruciani et al. 2009; de Vries-Sluijs et al. 2008; Fonseca et al. 2005; Pasricha et al. 2006), (b) adding an extra (boosting) dose when the standard three-dose regimen fails to induce protective Ab response (Cruciani et al. 2009; Rey et al. 2000), and (c) using immunoregulatory cytokine or unmethylated CpG oligonucleotide as an adjuvant in one of the priming doses (Cooper et al. 2008; Sasaki et al. 2003).
###end p 5
###begin p 6
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">2001</xref>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 36 39 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 228 231 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 396 401 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 417 422 <span type="species:ncbi:9606">human</span>
###xml 710 713 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 865 868 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Suboptimal Ab response to full-dose HBV vaccination was common in adolescents and youth enrolled by the Reaching for Excellence in Adolescent Care and Health (REACH) study supported by the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) (Wang et al. 2004; Wilson et al. 2001). Key factors associated with this unfavorable outcome included: (1) immunodeficiency as a result of HIV-1 infection, (2) human leukocyte antigen (HLA) class II genotype, especially DRB1*07, and (3) promoter sequence variations in several cytokine genes (Wang et al. 2004). To confirm and refine some of these findings, new interventional studies nested within ATN have enrolled youth for prospective evaluation of HBV vaccination. These studies have facilitated the systematic analyses of HLA class II alleles and haplotypes in relation to differential Ab responses to HBV vaccination. Genotypes defined by non-coding, single nucleotide polymorphisms (SNPs) within and beyond the HLA class II region can also be tested for their potential associations.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
Study populations
###end title 8
###begin p 9
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 195 203 195 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="app" rid="App1">Appendix</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 692 693 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1287 1294 1287 1294 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1294 1400 1294 1400 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="10">Characteristics of 335 youth with defined peak antibody (Ab) response to full-dose hepatitis B vaccination</p>
###xml 1294 1400 1294 1400 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="10">Characteristics of 335 youth with defined peak antibody (Ab) response to full-dose hepatitis B vaccination</p></caption>
###xml 1400 1400 1400 1400 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1420 1421 1420 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1400 1428 1400 1428 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HIV-1 seropositive (<italic>N</italic>&#160;=&#160;255)</th>
###xml 1448 1449 1448 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1428 1455 1428 1455 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HIV-1 seronegative (<italic>N</italic>&#160;=&#160;80)</th>
###xml 1455 1456 1455 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1462 1463 1462 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1455 1463 1455 1463 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic> value<sup>a</sup></th>
###xml 1400 1463 1400 1463 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">HIV-1 seropositive (<italic>N</italic>&#160;=&#160;255)</th><th align="left">HIV-1 seronegative (<italic>N</italic>&#160;=&#160;80)</th><th align="left"><italic>P</italic> value<sup>a</sup></th></tr>
###xml 1400 1463 1400 1463 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">HIV-1 seropositive (<italic>N</italic>&#160;=&#160;255)</th><th align="left">HIV-1 seronegative (<italic>N</italic>&#160;=&#160;80)</th><th align="left"><italic>P</italic> value<sup>a</sup></th></tr></thead>
###xml 1463 1489 1463 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Baseline age (mean&#160;&#177;&#160;SD)</td>
###xml 1489 1501 1487 1497 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">20.9&#160;&#177;&#160;0.2</td>
###xml 1501 1513 1497 1507 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15.8&#160;&#177;&#160;0.2</td>
###xml 1513 1520 1507 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1463 1520 1463 1514 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Baseline age (mean&#160;&#177;&#160;SD)</td><td align="left">20.9&#160;&#177;&#160;0.2</td><td align="left">15.8&#160;&#177;&#160;0.2</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 1520 1535 1514 1529 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sex ratio (F/M)</td>
###xml 1535 1548 1529 1542 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.60 (157/98)</td>
###xml 1548 1560 1542 1554 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.57 (29/51)</td>
###xml 1560 1567 1554 1561 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1520 1567 1514 1561 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Sex ratio (F/M)</td><td align="left">1.60 (157/98)</td><td align="left">0.57 (29/51)</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 1567 1590 1561 1584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Race/ethnicity combined</td>
###xml 1590 1590 1584 1584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1590 1595 1584 1589 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.230</td>
###xml 1567 1595 1561 1589 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Race/ethnicity combined</td><td align="left" colspan="2"/><td char="." align="char">0.230</td></tr>
###xml 1595 1615 1589 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Black, non-Hispanic</td>
###xml 1615 1624 1609 1618 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">76 (29.8)</td>
###xml 1624 1634 1618 1628 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">17 (21.3%)</td>
###xml 1634 1634 1628 1628 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="4"/>
###xml 1595 1634 1589 1628 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Black, non-Hispanic</td><td align="left">76 (29.8)</td><td align="left">17 (21.3%)</td><td char="." align="char" rowspan="4"/></tr>
###xml 1654 1655 1648 1649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1634 1655 1628 1649 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;White, non-Hispanic<sup>b</sup></td>
###xml 1655 1662 1649 1656 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (2.8)</td>
###xml 1662 1669 1656 1663 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (2.5)</td>
###xml 1634 1669 1628 1663 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;White, non-Hispanic<sup>b</sup></td><td align="left">7 (2.8)</td><td align="left">2 (2.5)</td></tr>
###xml 1669 1695 1663 1689 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Hispanic (Black or White)</td>
###xml 1695 1705 1689 1699 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">169 (66.3)</td>
###xml 1705 1714 1699 1708 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60 (75.0)</td>
###xml 1669 1714 1663 1708 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Hispanic (Black or White)</td><td align="left">169 (66.3)</td><td align="left">60 (75.0)</td></tr>
###xml 1721 1722 1715 1716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1714 1722 1708 1716 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Others<sup>b</sup></td>
###xml 1722 1729 1716 1723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3 (1.2)</td>
###xml 1729 1736 1723 1730 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1 (1.3)</td>
###xml 1714 1736 1708 1730 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Others<sup>b</sup></td><td align="left">3 (1.2)</td><td align="left">1 (1.3)</td></tr>
###xml 1747 1748 1741 1742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1736 1748 1730 1742 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ab response<sup>c</sup></td>
###xml 1748 1748 1742 1742 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1748 1755 1742 1749 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1736 1755 1730 1749 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Ab response<sup>c</sup></td><td align="left" colspan="2"/><td char="." align="char">&lt;0.0001</td></tr>
###xml 1755 1774 1749 1768 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Non-responder (NR)</td>
###xml 1774 1784 1768 1778 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">74 (29.0%)</td>
###xml 1784 1792 1778 1786 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (5.0%)</td>
###xml 1792 1792 1786 1786 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="3"/>
###xml 1755 1792 1749 1786 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Non-responder (NR)</td><td align="left">74 (29.0%)</td><td align="left">4 (5.0%)</td><td char="." align="char" rowspan="3"/></tr>
###xml 1792 1814 1786 1808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Medium responder (MR)</td>
###xml 1814 1825 1808 1819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">121 (47.5%)</td>
###xml 1825 1835 1819 1829 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">39 (48.8%)</td>
###xml 1792 1835 1786 1829 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Medium responder (MR)</td><td align="left">121 (47.5%)</td><td align="left">39 (48.8%)</td></tr>
###xml 1835 1856 1829 1850 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;High responders (HR)</td>
###xml 1856 1866 1850 1860 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60 (23.5%)</td>
###xml 1866 1876 1860 1870 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">37 (46.3%)</td>
###xml 1835 1876 1829 1870 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;High responders (HR)</td><td align="left">60 (23.5%)</td><td align="left">37 (46.3%)</td></tr>
###xml 1463 1876 1463 1870 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Baseline age (mean&#160;&#177;&#160;SD)</td><td align="left">20.9&#160;&#177;&#160;0.2</td><td align="left">15.8&#160;&#177;&#160;0.2</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Sex ratio (F/M)</td><td align="left">1.60 (157/98)</td><td align="left">0.57 (29/51)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Race/ethnicity combined</td><td align="left" colspan="2"/><td char="." align="char">0.230</td></tr><tr><td align="left">&#160;Black, non-Hispanic</td><td align="left">76 (29.8)</td><td align="left">17 (21.3%)</td><td char="." align="char" rowspan="4"/></tr><tr><td align="left">&#160;White, non-Hispanic<sup>b</sup></td><td align="left">7 (2.8)</td><td align="left">2 (2.5)</td></tr><tr><td align="left">&#160;Hispanic (Black or White)</td><td align="left">169 (66.3)</td><td align="left">60 (75.0)</td></tr><tr><td align="left">&#160;Others<sup>b</sup></td><td align="left">3 (1.2)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">Ab response<sup>c</sup></td><td align="left" colspan="2"/><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">&#160;Non-responder (NR)</td><td align="left">74 (29.0%)</td><td align="left">4 (5.0%)</td><td char="." align="char" rowspan="3"/></tr><tr><td align="left">&#160;Medium responder (MR)</td><td align="left">121 (47.5%)</td><td align="left">39 (48.8%)</td></tr><tr><td align="left">&#160;High responders (HR)</td><td align="left">60 (23.5%)</td><td align="left">37 (46.3%)</td></tr></tbody>
###xml 1400 1876 1400 1870 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">HIV-1 seropositive (<italic>N</italic>&#160;=&#160;255)</th><th align="left">HIV-1 seronegative (<italic>N</italic>&#160;=&#160;80)</th><th align="left"><italic>P</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td align="left">Baseline age (mean&#160;&#177;&#160;SD)</td><td align="left">20.9&#160;&#177;&#160;0.2</td><td align="left">15.8&#160;&#177;&#160;0.2</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Sex ratio (F/M)</td><td align="left">1.60 (157/98)</td><td align="left">0.57 (29/51)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Race/ethnicity combined</td><td align="left" colspan="2"/><td char="." align="char">0.230</td></tr><tr><td align="left">&#160;Black, non-Hispanic</td><td align="left">76 (29.8)</td><td align="left">17 (21.3%)</td><td char="." align="char" rowspan="4"/></tr><tr><td align="left">&#160;White, non-Hispanic<sup>b</sup></td><td align="left">7 (2.8)</td><td align="left">2 (2.5)</td></tr><tr><td align="left">&#160;Hispanic (Black or White)</td><td align="left">169 (66.3)</td><td align="left">60 (75.0)</td></tr><tr><td align="left">&#160;Others<sup>b</sup></td><td align="left">3 (1.2)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">Ab response<sup>c</sup></td><td align="left" colspan="2"/><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">&#160;Non-responder (NR)</td><td align="left">74 (29.0%)</td><td align="left">4 (5.0%)</td><td char="." align="char" rowspan="3"/></tr><tr><td align="left">&#160;Medium responder (MR)</td><td align="left">121 (47.5%)</td><td align="left">39 (48.8%)</td></tr><tr><td align="left">&#160;High responders (HR)</td><td align="left">60 (23.5%)</td><td align="left">37 (46.3%)</td></tr></tbody></table>
###xml 1876 1877 1870 1871 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1926 1927 1920 1921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1876 1987 1870 1981 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11"><sup>a</sup>By comparing the two patient groups using either <italic>t</italic> test (for age) or logistic regression (for other variables)</p>
###xml 1987 1988 1981 1982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1987 2048 1981 2042 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="12"><sup>b</sup>Treated as one group in subsequent analyses (e.g., Table S2)</p>
###xml 2048 2049 2042 2043 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2048 2224 2042 2218 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="13"><sup>c</sup>Non-responders have serum Ab concentrations &lt;10&#160;mIU/mL at week 28 (4&#160;weeks after last dose of vaccination); medium responders at 10&#8211;1,000&#160;mIU/mL; high responders &gt;1,000&#160;mIU/mL</p>
###xml 1876 2224 1870 2218 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11"><sup>a</sup>By comparing the two patient groups using either <italic>t</italic> test (for age) or logistic regression (for other variables)</p><p textid="12"><sup>b</sup>Treated as one group in subsequent analyses (e.g., Table S2)</p><p textid="13"><sup>c</sup>Non-responders have serum Ab concentrations &lt;10&#160;mIU/mL at week 28 (4&#160;weeks after last dose of vaccination); medium responders at 10&#8211;1,000&#160;mIU/mL; high responders &gt;1,000&#160;mIU/mL</p></table-wrap-foot>
###xml 1287 2224 1287 2218 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="10">Characteristics of 335 youth with defined peak antibody (Ab) response to full-dose hepatitis B vaccination</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">HIV-1 seropositive (<italic>N</italic>&#160;=&#160;255)</th><th align="left">HIV-1 seronegative (<italic>N</italic>&#160;=&#160;80)</th><th align="left"><italic>P</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td align="left">Baseline age (mean&#160;&#177;&#160;SD)</td><td align="left">20.9&#160;&#177;&#160;0.2</td><td align="left">15.8&#160;&#177;&#160;0.2</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Sex ratio (F/M)</td><td align="left">1.60 (157/98)</td><td align="left">0.57 (29/51)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Race/ethnicity combined</td><td align="left" colspan="2"/><td char="." align="char">0.230</td></tr><tr><td align="left">&#160;Black, non-Hispanic</td><td align="left">76 (29.8)</td><td align="left">17 (21.3%)</td><td char="." align="char" rowspan="4"/></tr><tr><td align="left">&#160;White, non-Hispanic<sup>b</sup></td><td align="left">7 (2.8)</td><td align="left">2 (2.5)</td></tr><tr><td align="left">&#160;Hispanic (Black or White)</td><td align="left">169 (66.3)</td><td align="left">60 (75.0)</td></tr><tr><td align="left">&#160;Others<sup>b</sup></td><td align="left">3 (1.2)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">Ab response<sup>c</sup></td><td align="left" colspan="2"/><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">&#160;Non-responder (NR)</td><td align="left">74 (29.0%)</td><td align="left">4 (5.0%)</td><td char="." align="char" rowspan="3"/></tr><tr><td align="left">&#160;Medium responder (MR)</td><td align="left">121 (47.5%)</td><td align="left">39 (48.8%)</td></tr><tr><td align="left">&#160;High responders (HR)</td><td align="left">60 (23.5%)</td><td align="left">37 (46.3%)</td></tr></tbody></table><table-wrap-foot><p textid="11"><sup>a</sup>By comparing the two patient groups using either <italic>t</italic> test (for age) or logistic regression (for other variables)</p><p textid="12"><sup>b</sup>Treated as one group in subsequent analyses (e.g., Table S2)</p><p textid="13"><sup>c</sup>Non-responders have serum Ab concentrations &lt;10&#160;mIU/mL at week 28 (4&#160;weeks after last dose of vaccination); medium responders at 10&#8211;1,000&#160;mIU/mL; high responders &gt;1,000&#160;mIU/mL</p></table-wrap-foot></table-wrap>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 101 106 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 122 125 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 248 251 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 316 319 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
###xml 550 558 <span type="species:ncbi:9606">patients</span>
###xml 689 692 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1022 1030 <span type="species:ncbi:9606">patients</span>
###xml 1107 1114 <span type="species:ncbi:9606">patient</span>
###xml 1428 1433 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1898 1905 <span type="species:ncbi:9606">patient</span>
Between February 2006 and June 2008, 255 HIV-1 seropositive (HIV+) youth (12-24 years of age) and 80 HIV-1 seronegatives (HIV-) (12-17 years of age) were enrolled at 22 clinical sites (listed in Appendix) into prospective studies () (Table 1). The HIV- subjects were recruited from the US and Puerto Rico, while the HIV+ youth came from US, Puerto Rico, Brazil, and South Africa. The primary objective was to evaluate genetic influences on peak Ab responses in patients with three full doses of hepatitis B vaccination, based on analyses of eligible patients who were free of hepatitis before completing full vaccination regimens within the first 24 weeks (6 months) after enrollment. For HIV+ youth, their baseline CD4+ T cell counts were also measured as potential covariates for immune responses. This study was first approved by the Institutional Review Board (IRB) at University of Alabama at Birmingham (UAB), as protocol F051212004. Additional IRB approval was obtained from each participating clinical site before patients were asked to provide written informed consent for participation. Import of patient specimens from international sites in Brazil and South Africa to US was approved by the Centers for Disease Control and Prevention (permit no. 2006-12-053 and 2007-12-015).Table 1Characteristics of 335 youth with defined peak antibody (Ab) response to full-dose hepatitis B vaccinationHIV-1 seropositive (N = 255)HIV-1 seronegative (N = 80)P valueaBaseline age (mean +/- SD)20.9 +/- 0.215.8 +/- 0.2<0.0001Sex ratio (F/M)1.60 (157/98)0.57 (29/51)<0.0001Race/ethnicity combined0.230 Black, non-Hispanic76 (29.8)17 (21.3%) White, non-Hispanicb7 (2.8)2 (2.5) Hispanic (Black or White)169 (66.3)60 (75.0) Othersb3 (1.2)1 (1.3)Ab responsec<0.0001 Non-responder (NR)74 (29.0%)4 (5.0%) Medium responder (MR)121 (47.5%)39 (48.8%) High responders (HR)60 (23.5%)37 (46.3%)aBy comparing the two patient groups using either t test (for age) or logistic regression (for other variables)bTreated as one group in subsequent analyses (e.g., Table S2)cNon-responders have serum Ab concentrations <10 mIU/mL at week 28 (4 weeks after last dose of vaccination); medium responders at 10-1,000 mIU/mL; high responders >1,000 mIU/mL
###end p 9
###begin p 10
Characteristics of 335 youth with defined peak antibody (Ab) response to full-dose hepatitis B vaccination
###end p 10
###begin p 11
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 22 29 <span type="species:ncbi:9606">patient</span>
aBy comparing the two patient groups using either t test (for age) or logistic regression (for other variables)
###end p 11
###begin p 12
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bTreated as one group in subsequent analyses (e.g., Table S2)
###end p 12
###begin p 13
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cNon-responders have serum Ab concentrations <10 mIU/mL at week 28 (4 weeks after last dose of vaccination); medium responders at 10-1,000 mIU/mL; high responders >1,000 mIU/mL
###end p 13
###begin title 14
Quantification and categorization of serum Ab concentration
###end title 14
###begin p 15
###xml 597 605 <span type="species:ncbi:9606">Patients</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
Using serum sample drawn at week 28, i.e., 4 weeks after the final recommended dose of vaccine, Ab specific for HBsAg was measured in a central laboratory (Quest Diagnostics Inc., Baltimore, MD), using two commercial assays that differ in their lower limits of detection (LLD) (3 and 5 mIU/mL). The vast majority (98.5%) of samples were tested using the second assay, which provided an upper limit of detection (ULD) at 1,000 mIU/mL. A small number of subjects had no remaining serum to allow re-measure and so these subjects only had Ab results reported using the first test (ULD at 150 mIU/mL). Patients with peak serum Ab concentration less than 10 mIU/mL (the minimum protection level) were classified as non-responders (NR). Those with Ab concentrations ranging from 10 to 1,000 mIU/mL were designated as medium responders (MR), while high responders (HR) were the remainder of patients with Ab concentrations over 1,000 mIU/mL.
###end p 15
###begin title 16
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 85 90 <span type="species:ncbi:9606">human</span>
PCR-based genotyping of three HLA class II genes (HLA-DRB1, -DQA1, and -DQB1) in the human major histocompatibility complex (MHC)
###end title 16
###begin p 17
###xml 105 113 105 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1</italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 456 464 456 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 673 681 673 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 977 981 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">2004</xref>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">2004</xref>
###xml 1001 1005 1001 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2008</xref>
###xml 1277 1281 1277 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2005</xref>
###xml 1329 1333 1329 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2007</xref>
###xml 1352 1356 1352 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">1999</xref>
###xml 1371 1375 1371 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2006</xref>
###xml 1391 1395 1391 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2003</xref>
###xml 2160 2164 2160 2164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2006</xref>
Using DNA extracted from whole blood or buffy coat (PureGen kits from Gentra/Qiagen, Valencia, CA, USA), HLA-DQA1 and -DQB1 alleles were resolved with automated hybridization of sequence-specific oligonucleotide (SSO) probes to gene-specific PCR amplicons (Innogenetics Inc., Alphartetta, GA). Tests were facilitated by the Auto LiPA 30 system, under conditions recommended by the manufacturer (Innogenetics). A total of 35 and 37 SSO probes were used for HLA-DQA1 and -DQB1 typing, respectively. Homozygosity was confirmed and ambiguities with SSO results were resolved by sequencing-based typing (SBT), using commercial kits from Abbott Molecular Inc. (Des Plaines, IL). HLA-DRB1 genotyping began with SBT (Abbott Molecular Inc.), with ambiguities resolved by SSO assays (57 probes) (Innogenetics). The same or similar genotyping techniques had been applied extensively in earlier studies involving samples from African, European, and North American populations (Shao et al. 2004; Tang et al. 2004, 2008). The final allele assignments for the three HLA class II genes considered two major functional properties. First, allele groups defined by the first two-digit designations (e.g., DRB1*01) often correspond to serological specificities (as alloantigens) (Schreuder et al. 2005) or shared motifs and lineages (Agrawal et al. 2007; Bergstrom et al. 1999; Dorak et al. 2006; Hohjoh et al. 2003). Second, alleles with four-digit designations (e.g., DRB1*0101, *0102, and *0103) define functional units that differ in amino acid sequences and the protein structure. Higher (six-digit) resolution like DRB1*010201 was also achievable for various alleles in the study population, with the 5th and 6th digits capturing additional, synonymous DNA polymorphisms. However, only DRB1*1101 had multiple common alleles with different six-digit designations (i.e., *110101 and *110102) in the study population. Further intronic sequence polymorphisms reflected by the 7th and 8th digits were not considered because intronic sequences were not part of our HLA genotyping strategies and because only a small number of alleles have such known designations (Robinson et al. 2006).
###end p 17
###begin title 18
Computational assignment of HLA class II haplotypes
###end title 18
###begin p 19
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 380 381 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
Following resolution of individual HLA alleles at each locus, linkage disequilibrium (LD) between specific HLA allele groups (two-digit designations) and alleles (four-digit designations) at neighboring loci were determined by relative difference (D') between the observed and expected frequencies of co-existence (presence) on the same chromosome or by correlation coefficients (r). Two-locus haplotype assignments were based on the expectation-maximization (EM) algorithm in SAS Genetics (SAS Institute, Cary, NC), which was further applied to the evaluation of extended, three-locus haplotypes. All haplotypes assigned computationally were unambiguous, with statistical probability exceeding 99%.
###end p 19
###begin title 20
Primary association analyses of HLA class II variants
###end title 20
###begin p 21
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1161 1162 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 199 206 <span type="species:ncbi:9606">patient</span>
###xml 242 247 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
Using SAS program package, version 9.2 (including SAS Genetics) (SAS Institute), the distribution of HLA class II alleles and haplotypes was first assessed for Hardy-Weinberg equilibrium (HWE) among patient groups defined by race, ethnicity, HIV-1 infection status, and Ab responses (NR, MR, and HR). Population (marker) frequencies of HLA allele groups, alleles, and their haplotypes were then compared across the three groups of patients defined by Ab responses. Individual variants with nominal P < 0.050 in univariate tests for trend (logit procedure) were further evaluated in multivariable logistic regression models. Different model selection procedures (backward, forward, stepwise) were applied until a reduced model could sufficiently capture all independent predictors of the responder phenotype. The summary statistical measures included effective sample sizes as well as strengths of associations, as indicated by beta estimates (mean +/- standard error), proportional odds ratio (pOR) across three Ab response groups (HR, MR, and NR), OR for being responders (HR + MR vs. NR), 95% confidence interval (CI) for all pOR and OR estimates, along with P values (either nominal or adjusted).
###end p 21
###begin title 22
Genotyping of SNPs within and beyond the HLA class II region
###end title 22
###begin p 23
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNRD1</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-C</italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2007</xref>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2009</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2008</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2009</xref>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">2009</xref>
###xml 529 532 529 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 534 537 534 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LTA</italic>
###xml 543 546 543 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LTB</italic>
###xml 863 867 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2006</xref>
###xml 1563 1564 1549 1550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1564 1565 1550 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1585 1586 1569 1570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1586 1587 1570 1571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1743 1747 1727 1731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2006</xref>
###xml 1763 1767 1747 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2007</xref>
###xml 249 254 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Single nucleotide polymorphism selection focused on three major genomic blocks within and between HLA class I and class II genes (Table S1). The first (HLA class I region) has three genes (ZNRD1, HLA-C, and HCP5) recently implicated as important to HIV-1 pathogenesis in several genome-wide association studies (Dalmasso et al. 2008; Fellay et al. 2007; Limou et al. 2009) and additional follow-up studies (Catano et al. 2008; Shrestha et al. 2009; van Manen et al. 2009). The second (central HLA region) has a cluster of genes (TNF, LTA, and LTB) encoding tumor necrosis factor alpha (TNF-alpha), lymphotoxin alpha (LT-alpha or TNF-beta), and LT-beta that regulate inflammatory responses. The third (HLA class II region) has multiple non-coding SNPs that can effectively tag HLA class II alleles associated with autoimmune and related diseases (de Bakker et al. 2006). Gene-specific SNPs in HLA class I and central regions were selected in five steps. First, SNPs assembled through SNPper () were filtered to allow an initial focus on "functional SNPs" with a potential phenotypic effect, including those located in exons, transcription factor binding sites, and intron/exon boundaries. Second, SNPs with minor allele frequencies (MAF) <0.02 in any of the three major populations (Africans, Asians, and Europeans) targeted by the International HapMap Project () were excluded for lack of statistical power. Third, the Tagger program () was applied to select additional tagging SNPs (tagSNPs) that would capture multiple SNPs using a stringent tagging algorithm (r2 >/= 0.8), with the r2 values derived from the HapMap project or the Perlegen Genotype Browser (). Fourth, SNPs commonly analyzed in earlier population studies (de Bakker et al. 2006; Fellay et al. 2007) were added to serve as benchmarks that could facilitate inter-cohort comparisons. Fifth, SNPs chosen after the first four steps were evaluated for their respective suitability for bead array-based genotyping (Goldengate SNP typing assay) at Illumina (San Diego, CA). SNPs predicted to have low (<50%) success rates were replaced by new ones of equal tagging capabilities. The last (fifth) step was repeated twice to yield a total of 88 (3 coding and 85 non-coding) SNPs (Table S1) for high-throughput genotyping, with quality control facilitated by previously genotyped reference DNA and by random duplicates of DNA samples derived from the study population.
###end p 23
###begin title 24
Statistical approach to analyzing SNP genotypes
###end title 24
###begin p 25
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 895 896 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 914 916 912 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 1119 1120 1117 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
For each of the 88 MHC SNPs analyzed here, homozygous and heterozygous genotypes were tested in 3 x 3 and 3 x 2 contingency tables, i.e., patients with (2 or 1 copy) and without (0 copy) the minor allele at each locus were stratified by the three levels of Ab response (NR, MR, and HR). A nominal P value < 0.050 in Chi-square test was considered indicative of possible associations and all neighboring SNPs were evaluated jointly for potential involvement of local haplotypes. Evaluation of the relative and independent contribution of SNP alleles and haplotypes required statistical adjustments for HLA and non-genetic factors revealed by primary association analyses. Given the multiple testing of 88 target SNPs, about four random (false positive) discoveries were anticipated when type I statistical error was accepted at the 0.050 level, while a truly probable association would require a P value </=5.7 x 10-4 to withstand correction for multiple comparisons. As a compromise between least and most stringent evaluations, formal multivariable statistical models were considered useful only for SNP variants with P < 0.001 in the initial univariate tests.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics and assessment of non-genetic factors in Ab responses
###end title 27
###begin p 28
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 99 102 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 201 204 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 295 298 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Among the 255 HIV-1 seropositive (HIV+) and 80 seronegative (HIV-) youth enrolled into this study, HIV- individuals had a mean age of 15.8 years and they were mostly male (63.8%) and Hispanic (75.0%). HIV+ individuals were slightly older (average age = 20.9 years, P < 0.0001 when compared with HIV- subjects) and they were mostly female (61.6%) and Hispanic (66.3%).
###end p 28
###begin p 29
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">2001</xref>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 157 158 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 529 533 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 585 586 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 835 836 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1025 1032 1020 1027 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1032 1176 1027 1171 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Univariate and multivariable models to compare relative impact of HIV-1 infection and HLA allelic variants on antibody responses among 335 youth</p>
###xml 1032 1176 1027 1171 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Univariate and multivariable models to compare relative impact of HIV-1 infection and HLA allelic variants on antibody responses among 335 youth</p></caption>
###xml 1176 1196 1171 1191 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Factors (covariates)</th>
###xml 1196 1197 1191 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1196 1197 1191 1192 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>n</italic></th>
###xml 1216 1217 1211 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1197 1217 1192 1212 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Univariate analyses<sup>a</sup></th>
###xml 1238 1239 1233 1234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1217 1239 1212 1234 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Multivariable model 1<sup>b</sup></th>
###xml 1260 1261 1255 1256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1239 1261 1234 1256 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Multivariable model 2<sup>b</sup></th>
###xml 1176 1261 1171 1256 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Univariate analyses<sup>a</sup></th><th align="left" colspan="4">Multivariable model 1<sup>b</sup></th><th align="left" colspan="4">Multivariable model 2<sup>b</sup></th></tr>
###xml 1261 1265 1256 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1261 1272 1256 1262 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1272 1273 1262 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1272 1273 1262 1263 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1273 1276 1263 1266 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 1276 1282 1266 1272 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1282 1286 1272 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1282 1293 1272 1278 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1293 1294 1278 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1293 1294 1278 1279 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1294 1297 1279 1282 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 1297 1303 1282 1288 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1303 1307 1288 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1303 1314 1288 1294 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1314 1315 1294 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1314 1315 1294 1295 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1315 1318 1295 1298 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 1318 1324 1298 1304 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1261 1324 1256 1304 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr>
###xml 1176 1324 1171 1304 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Univariate analyses<sup>a</sup></th><th align="left" colspan="4">Multivariable model 1<sup>b</sup></th><th align="left" colspan="4">Multivariable model 2<sup>b</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead>
###xml 1324 1339 1304 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HIV-1 infection</td>
###xml 1339 1342 1319 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">255</td>
###xml 1342 1356 1322 1334 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.61&#160;&#177;&#160;0.13</td>
###xml 1356 1363 1334 1341 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1363 1367 1341 1345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.29</td>
###xml 1367 1376 1345 1354 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.18&#8211;0.48</td>
###xml 1376 1390 1354 1366 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.60&#160;&#177;&#160;0.16</td>
###xml 1390 1395 1366 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.002</td>
###xml 1395 1399 1371 1375 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.30</td>
###xml 1399 1408 1375 1384 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.16&#8211;0.56</td>
###xml 1408 1422 1384 1396 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.59&#160;&#177;&#160;0.16</td>
###xml 1422 1428 1396 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1428 1432 1402 1406 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.31</td>
###xml 1432 1441 1406 1415 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.16&#8211;0.57</td>
###xml 1324 1441 1304 1415 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HIV-1 infection</td><td char="." align="char">255</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.13</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.29</td><td char="&#8211;" align="char">0.18&#8211;0.48</td><td align="left">&#8722;0.60&#160;&#177;&#160;0.16</td><td char="." align="char">0.002</td><td char="." align="char">0.30</td><td char="&#8211;" align="char">0.16&#8211;0.56</td><td align="left">&#8722;0.59&#160;&#177;&#160;0.16</td><td char="." align="char">&lt;0.001</td><td align="left">0.31</td><td char="&#8211;" align="char">0.16&#8211;0.57</td></tr>
###xml 1448 1449 1422 1423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1441 1449 1415 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DRB1*03<sup>c</sup></td>
###xml 1449 1451 1423 1425 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71</td>
###xml 1451 1465 1425 1437 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td>
###xml 1465 1470 1437 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 1470 1474 1442 1446 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.57</td>
###xml 1474 1483 1446 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.35&#8211;0.93</td>
###xml 1483 1497 1455 1467 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.55&#160;&#177;&#160;0.27</td>
###xml 1497 1502 1467 1472 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.040</td>
###xml 1502 1506 1472 1476 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.58</td>
###xml 1506 1515 1476 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.34&#8211;0.98</td>
###xml 1517 1518 1487 1488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1515 1518 1485 1488 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA<sup>c</sup></td>
###xml 1518 1518 1488 1488 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1520 1521 1490 1491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1518 1521 1488 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA<sup>c</sup></td>
###xml 1521 1521 1491 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1441 1521 1415 1491 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">DRB1*03<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.026</td><td char="." align="char">0.57</td><td char="&#8211;" align="char">0.35&#8211;0.93</td><td align="left">&#8722;0.55&#160;&#177;&#160;0.27</td><td char="." align="char">0.040</td><td char="." align="char">0.58</td><td char="&#8211;" align="char">0.34&#8211;0.98</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr>
###xml 1530 1531 1500 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1521 1531 1491 1501 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DRB1*0701<sup>c</sup></td>
###xml 1531 1533 1501 1503 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71</td>
###xml 1533 1547 1503 1515 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td>
###xml 1547 1552 1515 1520 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.043</td>
###xml 1552 1556 1520 1524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.60</td>
###xml 1556 1565 1524 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.37&#8211;0.98</td>
###xml 1565 1579 1533 1545 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.58&#160;&#177;&#160;0.26</td>
###xml 1579 1584 1545 1550 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.025</td>
###xml 1584 1588 1550 1554 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.56</td>
###xml 1588 1597 1554 1563 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.34&#8211;0.93</td>
###xml 1599 1600 1565 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1597 1600 1563 1566 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA<sup>c</sup></td>
###xml 1600 1600 1566 1566 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1602 1603 1568 1569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1600 1603 1566 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA<sup>c</sup></td>
###xml 1603 1603 1569 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1521 1603 1491 1569 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">DRB1*0701<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.043</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.37&#8211;0.98</td><td align="left">&#8722;0.58&#160;&#177;&#160;0.26</td><td char="." align="char">0.025</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.34&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr>
###xml 1603 1612 1569 1578 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DRB1*0804</td>
###xml 1612 1614 1578 1580 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1614 1627 1580 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.17&#160;&#177;&#160;0.44</td>
###xml 1627 1632 1591 1596 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.008</td>
###xml 1632 1636 1596 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.22</td>
###xml 1636 1645 1600 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.35&#8211;7.63</td>
###xml 1645 1658 1609 1620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.31&#160;&#177;&#160;0.47</td>
###xml 1658 1663 1620 1625 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.005</td>
###xml 1663 1667 1625 1629 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.69</td>
###xml 1667 1676 1629 1638 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.48&#8211;9.21</td>
###xml 1676 1689 1638 1649 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.37&#160;&#177;&#160;0.46</td>
###xml 1689 1694 1649 1654 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.003</td>
###xml 1694 1698 1654 1658 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.92</td>
###xml 1698 1707 1658 1667 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.59&#8211;9.69</td>
###xml 1603 1707 1569 1667 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">DRB1*0804</td><td char="." align="char">21</td><td char="&#177;" align="char">1.17&#160;&#177;&#160;0.44</td><td char="." align="char">0.008</td><td char="." align="char">3.22</td><td char="&#8211;" align="char">1.35&#8211;7.63</td><td align="left">1.31&#160;&#177;&#160;0.47</td><td char="." align="char">0.005</td><td char="." align="char">3.69</td><td char="&#8211;" align="char">1.48&#8211;9.21</td><td align="left">1.37&#160;&#177;&#160;0.46</td><td char="." align="char">0.003</td><td align="left">3.92</td><td char="&#8211;" align="char">1.59&#8211;9.69</td></tr>
###xml 1707 1714 1667 1674 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DQB1*02</td>
###xml 1714 1717 1674 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">116</td>
###xml 1717 1731 1677 1689 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.50&#160;&#177;&#160;0.22</td>
###xml 1731 1736 1689 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.020</td>
###xml 1736 1740 1694 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.60</td>
###xml 1740 1749 1698 1707 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.40&#8211;0.93</td>
###xml 1751 1752 1709 1710 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1749 1752 1707 1710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA<sup>c</sup></td>
###xml 1752 1752 1710 1710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1752 1752 1710 1710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1752 1752 1710 1710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1752 1766 1710 1722 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.37&#160;&#177;&#160;0.22</td>
###xml 1766 1771 1722 1727 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.100</td>
###xml 1771 1775 1727 1731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.69</td>
###xml 1775 1784 1731 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.45&#8211;1.08</td>
###xml 1707 1784 1667 1740 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">DQB1*02</td><td char="." align="char">116</td><td char="&#177;" align="char">&#8722;0.50&#160;&#177;&#160;0.22</td><td char="." align="char">0.020</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.40&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left">&#8722;0.37&#160;&#177;&#160;0.22</td><td char="." align="char">0.100</td><td align="left">0.69</td><td char="&#8211;" align="char">0.45&#8211;1.08</td></tr>
###xml 1324 1784 1304 1740 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">HIV-1 infection</td><td char="." align="char">255</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.13</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.29</td><td char="&#8211;" align="char">0.18&#8211;0.48</td><td align="left">&#8722;0.60&#160;&#177;&#160;0.16</td><td char="." align="char">0.002</td><td char="." align="char">0.30</td><td char="&#8211;" align="char">0.16&#8211;0.56</td><td align="left">&#8722;0.59&#160;&#177;&#160;0.16</td><td char="." align="char">&lt;0.001</td><td align="left">0.31</td><td char="&#8211;" align="char">0.16&#8211;0.57</td></tr><tr><td align="left">DRB1*03<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.026</td><td char="." align="char">0.57</td><td char="&#8211;" align="char">0.35&#8211;0.93</td><td align="left">&#8722;0.55&#160;&#177;&#160;0.27</td><td char="." align="char">0.040</td><td char="." align="char">0.58</td><td char="&#8211;" align="char">0.34&#8211;0.98</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr><tr><td align="left">DRB1*0701<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.043</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.37&#8211;0.98</td><td align="left">&#8722;0.58&#160;&#177;&#160;0.26</td><td char="." align="char">0.025</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.34&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr><tr><td align="left">DRB1*0804</td><td char="." align="char">21</td><td char="&#177;" align="char">1.17&#160;&#177;&#160;0.44</td><td char="." align="char">0.008</td><td char="." align="char">3.22</td><td char="&#8211;" align="char">1.35&#8211;7.63</td><td align="left">1.31&#160;&#177;&#160;0.47</td><td char="." align="char">0.005</td><td char="." align="char">3.69</td><td char="&#8211;" align="char">1.48&#8211;9.21</td><td align="left">1.37&#160;&#177;&#160;0.46</td><td char="." align="char">0.003</td><td align="left">3.92</td><td char="&#8211;" align="char">1.59&#8211;9.69</td></tr><tr><td align="left">DQB1*02</td><td char="." align="char">116</td><td char="&#177;" align="char">&#8722;0.50&#160;&#177;&#160;0.22</td><td char="." align="char">0.020</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.40&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left">&#8722;0.37&#160;&#177;&#160;0.22</td><td char="." align="char">0.100</td><td align="left">0.69</td><td char="&#8211;" align="char">0.45&#8211;1.08</td></tr></tbody>
###xml 1176 1784 1171 1740 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Univariate analyses<sup>a</sup></th><th align="left" colspan="4">Multivariable model 1<sup>b</sup></th><th align="left" colspan="4">Multivariable model 2<sup>b</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">HIV-1 infection</td><td char="." align="char">255</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.13</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.29</td><td char="&#8211;" align="char">0.18&#8211;0.48</td><td align="left">&#8722;0.60&#160;&#177;&#160;0.16</td><td char="." align="char">0.002</td><td char="." align="char">0.30</td><td char="&#8211;" align="char">0.16&#8211;0.56</td><td align="left">&#8722;0.59&#160;&#177;&#160;0.16</td><td char="." align="char">&lt;0.001</td><td align="left">0.31</td><td char="&#8211;" align="char">0.16&#8211;0.57</td></tr><tr><td align="left">DRB1*03<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.026</td><td char="." align="char">0.57</td><td char="&#8211;" align="char">0.35&#8211;0.93</td><td align="left">&#8722;0.55&#160;&#177;&#160;0.27</td><td char="." align="char">0.040</td><td char="." align="char">0.58</td><td char="&#8211;" align="char">0.34&#8211;0.98</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr><tr><td align="left">DRB1*0701<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.043</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.37&#8211;0.98</td><td align="left">&#8722;0.58&#160;&#177;&#160;0.26</td><td char="." align="char">0.025</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.34&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr><tr><td align="left">DRB1*0804</td><td char="." align="char">21</td><td char="&#177;" align="char">1.17&#160;&#177;&#160;0.44</td><td char="." align="char">0.008</td><td char="." align="char">3.22</td><td char="&#8211;" align="char">1.35&#8211;7.63</td><td align="left">1.31&#160;&#177;&#160;0.47</td><td char="." align="char">0.005</td><td char="." align="char">3.69</td><td char="&#8211;" align="char">1.48&#8211;9.21</td><td align="left">1.37&#160;&#177;&#160;0.46</td><td char="." align="char">0.003</td><td align="left">3.92</td><td char="&#8211;" align="char">1.59&#8211;9.69</td></tr><tr><td align="left">DQB1*02</td><td char="." align="char">116</td><td char="&#177;" align="char">&#8722;0.50&#160;&#177;&#160;0.22</td><td char="." align="char">0.020</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.40&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left">&#8722;0.37&#160;&#177;&#160;0.22</td><td char="." align="char">0.100</td><td align="left">0.69</td><td char="&#8211;" align="char">0.45&#8211;1.08</td></tr></tbody></table>
###xml 1784 1785 1740 1741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1846 1847 1802 1803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1784 2017 1740 1971 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><sup>a</sup>In analyses of three categories of antibody responses (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), summary statistical measures include beta estimate (mean&#160;&#177;&#160;standard error), proportional odds ratio (pOR), and 95% confidence interval (CI), as described in the text</p>
###xml 2017 2018 1971 1972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2017 2094 1971 2048 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><sup>b</sup>Age, ethnicity, and sex are treated as additional covariates in these models</p>
###xml 2094 2095 2048 2049 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2227 2229 2181 2183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 2094 2245 2048 2199 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><sup>c</sup>Strong linkage disequilibrium between these DRB1 variants and DQB1*02 (*0201 and *0202) precludes their presence in a single model (<italic>NA</italic> not applicable)</p>
###xml 1784 2245 1740 2199 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31"><sup>a</sup>In analyses of three categories of antibody responses (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), summary statistical measures include beta estimate (mean&#160;&#177;&#160;standard error), proportional odds ratio (pOR), and 95% confidence interval (CI), as described in the text</p><p textid="32"><sup>b</sup>Age, ethnicity, and sex are treated as additional covariates in these models</p><p textid="33"><sup>c</sup>Strong linkage disequilibrium between these DRB1 variants and DQB1*02 (*0201 and *0202) precludes their presence in a single model (<italic>NA</italic> not applicable)</p></table-wrap-foot>
###xml 1025 2245 1020 2199 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="30">Univariate and multivariable models to compare relative impact of HIV-1 infection and HLA allelic variants on antibody responses among 335 youth</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Univariate analyses<sup>a</sup></th><th align="left" colspan="4">Multivariable model 1<sup>b</sup></th><th align="left" colspan="4">Multivariable model 2<sup>b</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">HIV-1 infection</td><td char="." align="char">255</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.13</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.29</td><td char="&#8211;" align="char">0.18&#8211;0.48</td><td align="left">&#8722;0.60&#160;&#177;&#160;0.16</td><td char="." align="char">0.002</td><td char="." align="char">0.30</td><td char="&#8211;" align="char">0.16&#8211;0.56</td><td align="left">&#8722;0.59&#160;&#177;&#160;0.16</td><td char="." align="char">&lt;0.001</td><td align="left">0.31</td><td char="&#8211;" align="char">0.16&#8211;0.57</td></tr><tr><td align="left">DRB1*03<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.026</td><td char="." align="char">0.57</td><td char="&#8211;" align="char">0.35&#8211;0.93</td><td align="left">&#8722;0.55&#160;&#177;&#160;0.27</td><td char="." align="char">0.040</td><td char="." align="char">0.58</td><td char="&#8211;" align="char">0.34&#8211;0.98</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr><tr><td align="left">DRB1*0701<sup>c</sup></td><td char="." align="char">71</td><td char="&#177;" align="char">&#8722;0.56&#160;&#177;&#160;0.25</td><td char="." align="char">0.043</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.37&#8211;0.98</td><td align="left">&#8722;0.58&#160;&#177;&#160;0.26</td><td char="." align="char">0.025</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.34&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left">NA<sup>c</sup></td><td align="left"/></tr><tr><td align="left">DRB1*0804</td><td char="." align="char">21</td><td char="&#177;" align="char">1.17&#160;&#177;&#160;0.44</td><td char="." align="char">0.008</td><td char="." align="char">3.22</td><td char="&#8211;" align="char">1.35&#8211;7.63</td><td align="left">1.31&#160;&#177;&#160;0.47</td><td char="." align="char">0.005</td><td char="." align="char">3.69</td><td char="&#8211;" align="char">1.48&#8211;9.21</td><td align="left">1.37&#160;&#177;&#160;0.46</td><td char="." align="char">0.003</td><td align="left">3.92</td><td char="&#8211;" align="char">1.59&#8211;9.69</td></tr><tr><td align="left">DQB1*02</td><td char="." align="char">116</td><td char="&#177;" align="char">&#8722;0.50&#160;&#177;&#160;0.22</td><td char="." align="char">0.020</td><td char="." align="char">0.60</td><td char="&#8211;" align="char">0.40&#8211;0.93</td><td align="left">NA<sup>c</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left">&#8722;0.37&#160;&#177;&#160;0.22</td><td char="." align="char">0.100</td><td align="left">0.69</td><td char="&#8211;" align="char">0.45&#8211;1.08</td></tr></tbody></table><table-wrap-foot><p textid="31"><sup>a</sup>In analyses of three categories of antibody responses (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), summary statistical measures include beta estimate (mean&#160;&#177;&#160;standard error), proportional odds ratio (pOR), and 95% confidence interval (CI), as described in the text</p><p textid="32"><sup>b</sup>Age, ethnicity, and sex are treated as additional covariates in these models</p><p textid="33"><sup>c</sup>Strong linkage disequilibrium between these DRB1 variants and DQB1*02 (*0201 and *0202) precludes their presence in a single model (<italic>NA</italic> not applicable)</p></table-wrap-foot></table-wrap>
###xml 125 128 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 134 137 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 188 191 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 325 328 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 468 473 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 743 750 <span type="species:ncbi:9606">patient</span>
###xml 969 974 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1098 1103 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As seen in analyses of another youth population (Wang et al. 2004; Wilson et al. 2001), Ab response clearly differed between HIV+ and HIV- recipients (Table 1). More specifically, 5.0% of HIV- subjects were classified as NR (Ab concentration <10 mIU/mL), 48.8% as MR (10-1,000 mIU/mL), and 46.3% as HR (>1,000 mIU/mL), while HIV+ subjects had 29.0% NR, 47.5% MR, and 23.5% HR (overall P < 0.0001 by logistic regression). In univariate analysis, the negative impact of HIV-1 infection was clearly reflected by the mean parameter (beta) estimate and standard error (SE) (-0.61 +/- 0.13, P < 0.0001), along with the estimates of proportional odds ratio (pOR = 0.29) and 95% confidence interval (CI) (0.18-0.48) in test for trend across the three patient groups defined by high to low Ab responses (i.e., ordered as HR, MR, and NR) (Table 2). To minimize potential confounding by non-genetic factors, all subsequent association analyses considered age, sex, ethnicity, and HIV-1 infection status as cofactors (whenever possible).Table 2Univariate and multivariable models to compare relative impact of HIV-1 infection and HLA allelic variants on antibody responses among 335 youthFactors (covariates)nUnivariate analysesaMultivariable model 1bMultivariable model 2bbeta +/- SEPpOR95% CIbeta +/- SEPpOR95% CIbeta +/- SEPpOR95% CIHIV-1 infection255-0.61 +/- 0.13<0.00010.290.18-0.48-0.60 +/- 0.160.0020.300.16-0.56-0.59 +/- 0.16<0.0010.310.16-0.57DRB1*03c71-0.56 +/- 0.250.0260.570.35-0.93-0.55 +/- 0.270.0400.580.34-0.98NAcNAcDRB1*0701c71-0.56 +/- 0.250.0430.600.37-0.98-0.58 +/- 0.260.0250.560.34-0.93NAcNAcDRB1*0804211.17 +/- 0.440.0083.221.35-7.631.31 +/- 0.470.0053.691.48-9.211.37 +/- 0.460.0033.921.59-9.69DQB1*02116-0.50 +/- 0.220.0200.600.40-0.93NAc-0.37 +/- 0.220.1000.690.45-1.08aIn analyses of three categories of antibody responses (Table 1), summary statistical measures include beta estimate (mean +/- standard error), proportional odds ratio (pOR), and 95% confidence interval (CI), as described in the textbAge, ethnicity, and sex are treated as additional covariates in these modelscStrong linkage disequilibrium between these DRB1 variants and DQB1*02 (*0201 and *0202) precludes their presence in a single model (NA not applicable)
###end p 29
###begin p 30
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Univariate and multivariable models to compare relative impact of HIV-1 infection and HLA allelic variants on antibody responses among 335 youth
###end p 30
###begin p 31
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
aIn analyses of three categories of antibody responses (Table 1), summary statistical measures include beta estimate (mean +/- standard error), proportional odds ratio (pOR), and 95% confidence interval (CI), as described in the text
###end p 31
###begin p 32
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bAge, ethnicity, and sex are treated as additional covariates in these models
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 133 135 133 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
cStrong linkage disequilibrium between these DRB1 variants and DQB1*02 (*0201 and *0202) precludes their presence in a single model (NA not applicable)
###end p 33
###begin title 34
Distribution and LD of HLA class II variants
###end title 34
###begin p 35
###xml 102 110 102 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1</italic>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 571 579 571 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1</italic>
###xml 599 607 599 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 393 398 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Before any stratification, common allele groups found in at least ten individuals ranged from five at HLA-DQA1 and -DQB1 loci to 12 at the HLA-DRB1 locus. These allele groups contributed to 18 common DRB1-DQB1 haplotypes. Distribution of homozygous and heterozygous genotypes at each locus did not deviate from HWE, even for subsets of HLA typing results restricted to either racial groups or HIV-1 infection status (data not shown). Similarly, distribution of four-digit alleles also conformed to HWE, and the common alleles detected at each locus ranged from 12 at the HLA-DQA1 locus to 25 at the HLA-DRB1 locus. Twenty DRB1-DQB1 haplotypes were also common in tabulations based on the four-digit allelic designations.
###end p 35
###begin p 36
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 383 384 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 431 432 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 479 480 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 527 528 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 575 576 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 623 624 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 671 672 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 719 720 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 767 768 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 815 816 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 887 888 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
LD was quite strong for many four-digit alleles resolved at the three HLA class II loci, leading to the unambiguous (probability >99%) assignment of three-locus haplotypes in all 335 individuals. However, within the three main racial groups (Table 1), pairs of common alleles with strong enough LD (r2 >/= 0.80) to be mutually tagging were limited to (a) DRB1*0301 versus DQB1*0201 (r = 0.82-0.95), (b) DRB1*0301 versus DQA1*0501 (r = 0.92-1.00), (c) DRB1*0701 versus DQA1*0201 (r = 0.86-0.98), (d) DRB1*1101 versus DQA1*0105 (r = 0.72-0.94), (e) DRB1*1301 versus DQB1*0603 (r = 0.81-0.92), (f) DRB1*1401 versus DQA1*0104 (r = 0.92-1.00), (g) DRB1*1401 versus DQB1*0503 (r = 0.92-1.00), (h) DRB1*1402 versus DQB1*0503 (r = 0.89-0.92), (i) DRB1*1502 versus DQB1*0601 (r = 0.71-1.00), (j) DQA1*0501 versus DQB1*0201 (r = 0.83-0.96), and (k) DRB1*0301-DQB1*0201 haplotype versus DQA1*0501 (r = 0.92-1.00). These allele combinations and their two-digit allele groups were treated as joint entities in order to minimize the number of tests for genetic associations with variable Ab responses.
###end p 36
###begin p 37
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 176 177 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 324 325 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3 8 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 173 176 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 182 185 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 245 248 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 321 324 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
As HIV-1 infection status alone was a strong predictor of suboptimal Ab response, HLA class II alleles and haplotypes that were differentially (P < 0.050) distributed among HIV+ and HIV- subjects were also sorted (Table S2). Alleles enriched in HIV- subjects were DRB1*0407, DRB1*0802, and DQA1*0301. Alleles enriched in HIV+ subjects were DRB1*0804, DQA1*0103, DQB1*0503, and DQB1*0603 (Table S2).
###end p 37
###begin title 38
Individual HLA class II variants in relation to differential Ab responses in the entire study population
###end title 38
###begin p 39
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 663 664 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 681 685 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 717 718 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 837 841 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 850 851 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 919 920 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 927 931 917 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 949 950 934 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1138 1139 1123 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1146 1150 1131 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1168 1169 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1227 1228 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1234 1238 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1256 1257 1231 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1340 1341 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1355 1356 1330 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1382 1383 1355 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1397 1398 1370 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1411 1414 1382 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;10</sup>
###xml 1456 1460 1427 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 1503 1507 1474 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1526 1527 1492 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
###xml 1307 1315 <span type="species:ncbi:9606">patients</span>
Primary association analyses tested the key hypothesis that HLA class II alleles and/or haplotypes, especially those observed in another youth population (Wang et al. 2004), correlate with variable Ab response to hepatitis B vaccination, irrespective of other characteristics of the study population. After accounting for sample size (statistical power) and patterns of LD (genetic confounding), four allele groups stood out to be the most likely predictors of differential Ab responses (Table 2). First, DRB1*03 (mostly *0301 and *0302) and DRB1*07 (exclusively *0701) were negatively associated with the responder phenotype, with similar effective sample size (n = 71 for both), beta estimates (-0.56 for both) and P values (</=0.043), as well as similar pOR (</= 0.60). Second, DRB1*08 seen in 51 patients had a positive association (beta = 0.75, P = 0.010; pOR = 2.11, 95% CI = 1.20-3.72), mostly due to DRB1*0804 (n = 21, beta = 1.17 +/- 0.44, P = 0.008; pOR = 3.22, 95% CI = 1.35-7.63). In contrast, DRB1*0802 (Table S2) as another common allele in the DRB1*08 group did not show a clear trend for positive or negative association (n = 16, beta = 0.18 +/- 0.48, P > 0.70), neither did the less frequent allele DRB1*0801 (n = 9, beta = 0.74 +/- 0.64, P = 0.249). Third, DQB1*02, which was found in 116 patients and in LD with DRB1*03 (r = 0.32-0.43, P </= 0.0001) and DRB1*07 (r = 0.55-0.72, P </= 8.0 x 10-10), paralleled the associations of the two DRB1 allele, with similar parameter estimates (beta = -0.50 +/- 0.22, P = 0.020; pOR = 0.60, 95% CI = 0.40-0.93).
###end p 39
###begin p 40
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 204 209 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In multivariable models, the impact of three HLA-DRB1 variants on Ab responses was clearly independent of one another and these associations were insensitive to statistical adjustments for the effects of HIV-1 infection and other potential confounders (adjusted P = 0.005-0.040) (Table 2). Alternating DRB1*03 and DRB1*0701 with DQB1*02 did not change the parameter estimates for non-genetic factors and DRB1*0804, but it was evident that DQB1*02 itself was not a statistically significant factor (adjusted P = 0.100) (Table 2). Collectively, DRB1*03 and DRB1*0701 were found in 42 (53.8%) out of 78 NR, 65 (40.6%) out of 160 MR, and 27 (27.8%) out of 97 HR (P < 0.001 for trend).
###end p 40
###begin title 41
Evaluation of HLA haplotypes in the entire study population
###end title 41
###begin p 42
###xml 279 283 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 302 303 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 370 374 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 393 394 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 494 495 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 502 506 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 524 525 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 559 560 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 567 571 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 589 590 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 627 628 607 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 636 640 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 658 659 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 798 799 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Associations attributed to individual DRB1 alleles or allele groups were partially reflected by several DRB1-DQB1 haplotypes (Table S2). For example, the negative impact of DRB1*03 and DRB1*07 on Ab response was mostly due to the DRB1*03-DQB1*04 (DRB1*0302-DQB1*0402) haplotype (beta = -0.75 +/- 0.41, P = 0.067) and the DRB1*07-DQB1*02 (DRB1*0701-DQB1*0202) haplotype (beta = -0.48 +/- 0.26, P = 0.066), respectively. The positive association of DRB1*08 was mainly because of DRB1*08-DQB1*03 (n = 22, beta = 1.17 +/- 0.43, P = 0.007) or DRB1*0804-DQB1*0301 (n = 18, beta = 1.26 +/- 0.48, P = 0.009), but not DQB1*0301 itself (n = 108, beta = 0.23 +/- 0.22, P = 0.290). The parameter estimates for the major haplotypes involving DRB1*08 were highly comparable with those for DRB1*0804 alone (Table 2). Further analyses of extended (three-locus) haplotypes did not yield any definitive relationships.
###end p 42
###begin title 43
Two alternative models to allow inter-study comparisons
###end title 43
###begin p 44
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 249 250 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 352 353 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 567 571 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 744 745 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 782 786 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 824 825 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 994 1001 986 993 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1001 1098 993 1090 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Additional multivariable models to facilitate direct comparison with some of the earlier findings</p>
###xml 1001 1098 993 1090 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Additional multivariable models to facilitate direct comparison with some of the earlier findings</p></caption>
###xml 1098 1118 1090 1110 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Factors (covariates)</th>
###xml 1118 1119 1110 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1118 1119 1110 1111 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>n</italic></th>
###xml 1152 1153 1144 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1119 1153 1111 1145 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Alternative multivariable model 1<sup>a</sup></th>
###xml 1186 1187 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1153 1187 1145 1179 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Alternative multivariable model 2<sup>a</sup></th>
###xml 1098 1187 1090 1179 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Alternative multivariable model 1<sup>a</sup></th><th align="left" colspan="4">Alternative multivariable model 2<sup>a</sup></th></tr>
###xml 1187 1191 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1187 1198 1179 1185 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1198 1199 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1198 1199 1185 1186 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1199 1202 1186 1189 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 1202 1208 1189 1195 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1208 1212 1195 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1208 1219 1195 1201 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1219 1220 1201 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1219 1220 1201 1202 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1220 1222 1202 1204 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">OR</th>
###xml 1222 1228 1204 1210 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1187 1228 1179 1210 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">OR</th><th align="left">95% CI</th></tr>
###xml 1098 1228 1090 1210 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Alternative multivariable model 1<sup>a</sup></th><th align="left" colspan="4">Alternative multivariable model 2<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">OR</th><th align="left">95% CI</th></tr></thead>
###xml 1228 1243 1210 1225 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HIV-1 infection</td>
###xml 1243 1246 1225 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">228</td>
###xml 1246 1260 1228 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.44&#160;&#177;&#160;0.17</td>
###xml 1260 1265 1240 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.010</td>
###xml 1265 1269 1245 1249 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.42</td>
###xml 1269 1278 1249 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.22&#8211;0.81</td>
###xml 1278 1292 1258 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.73&#160;&#177;&#160;0.31</td>
###xml 1292 1297 1270 1275 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.021</td>
###xml 1297 1301 1275 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.23</td>
###xml 1301 1310 1279 1288 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.07&#8211;0.80</td>
###xml 1228 1310 1210 1288 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HIV-1 infection</td><td char="." align="char">228</td><td char="&#177;" align="char">&#8722;0.44&#160;&#177;&#160;0.17</td><td char="." align="char">0.010</td><td char="." align="char">0.42</td><td char="&#8211;" align="char">0.22&#8211;0.81</td><td align="left">&#8722;0.73&#160;&#177;&#160;0.31</td><td char="." align="char">0.021</td><td align="left">0.23</td><td char="&#8211;" align="char">0.07&#8211;0.80</td></tr>
###xml 1310 1322 1288 1300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="10">HLA variants</td>
###xml 1310 1322 1288 1300 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="10">HLA variants</td></tr>
###xml 1322 1330 1300 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*03</td>
###xml 1330 1332 1308 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67</td>
###xml 1332 1346 1310 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.78&#160;&#177;&#160;0.28</td>
###xml 1346 1351 1322 1327 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.006</td>
###xml 1351 1355 1327 1331 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.46</td>
###xml 1355 1364 1331 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.26&#8211;0.80</td>
###xml 1364 1378 1340 1352 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.88&#160;&#177;&#160;0.35</td>
###xml 1378 1383 1352 1357 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.013</td>
###xml 1383 1387 1357 1361 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.42</td>
###xml 1387 1396 1361 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.21&#8211;0.83</td>
###xml 1322 1396 1300 1370 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*03</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.78&#160;&#177;&#160;0.28</td><td char="." align="char">0.006</td><td char="." align="char">0.46</td><td char="&#8211;" align="char">0.26&#8211;0.80</td><td align="left">&#8722;0.88&#160;&#177;&#160;0.35</td><td char="." align="char">0.013</td><td align="left">0.42</td><td char="&#8211;" align="char">0.21&#8211;0.83</td></tr>
###xml 1396 1406 1370 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*0701</td>
###xml 1406 1408 1380 1382 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67</td>
###xml 1408 1422 1382 1394 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.84&#160;&#177;&#160;0.28</td>
###xml 1422 1427 1394 1399 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.002</td>
###xml 1427 1431 1399 1403 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.43</td>
###xml 1431 1440 1403 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.25&#8211;0.74</td>
###xml 1440 1454 1412 1424 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;1.03&#160;&#177;&#160;0.36</td>
###xml 1454 1459 1424 1429 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.005</td>
###xml 1459 1463 1429 1433 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.36</td>
###xml 1463 1472 1433 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.18&#8211;0.73</td>
###xml 1396 1472 1370 1442 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*0701</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.84&#160;&#177;&#160;0.28</td><td char="." align="char">0.002</td><td char="." align="char">0.43</td><td char="&#8211;" align="char">0.25&#8211;0.74</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.36</td><td char="." align="char">0.005</td><td align="left">0.36</td><td char="&#8211;" align="char">0.18&#8211;0.73</td></tr>
###xml 1482 1483 1452 1453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1472 1483 1442 1453 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*0804<sup>b</sup></td>
###xml 1483 1485 1453 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 1485 1498 1455 1466 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.37&#160;&#177;&#160;0.49</td>
###xml 1498 1503 1466 1471 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.006</td>
###xml 1503 1507 1471 1475 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.93</td>
###xml 1507 1517 1475 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.50&#8211;10.31</td>
###xml 1517 1519 1485 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1519 1519 1487 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1519 1521 1487 1489 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1521 1521 1489 1489 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1472 1521 1442 1489 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*0804<sup>b</sup></td><td char="." align="char">20</td><td char="&#177;" align="char">1.37&#160;&#177;&#160;0.49</td><td char="." align="char">0.006</td><td char="." align="char">3.93</td><td char="&#8211;" align="char">1.50&#8211;10.31</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr>
###xml 1228 1521 1210 1489 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">HIV-1 infection</td><td char="." align="char">228</td><td char="&#177;" align="char">&#8722;0.44&#160;&#177;&#160;0.17</td><td char="." align="char">0.010</td><td char="." align="char">0.42</td><td char="&#8211;" align="char">0.22&#8211;0.81</td><td align="left">&#8722;0.73&#160;&#177;&#160;0.31</td><td char="." align="char">0.021</td><td align="left">0.23</td><td char="&#8211;" align="char">0.07&#8211;0.80</td></tr><tr><td align="left" colspan="10">HLA variants</td></tr><tr><td align="left">&#160;DRB1*03</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.78&#160;&#177;&#160;0.28</td><td char="." align="char">0.006</td><td char="." align="char">0.46</td><td char="&#8211;" align="char">0.26&#8211;0.80</td><td align="left">&#8722;0.88&#160;&#177;&#160;0.35</td><td char="." align="char">0.013</td><td align="left">0.42</td><td char="&#8211;" align="char">0.21&#8211;0.83</td></tr><tr><td align="left">&#160;DRB1*0701</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.84&#160;&#177;&#160;0.28</td><td char="." align="char">0.002</td><td char="." align="char">0.43</td><td char="&#8211;" align="char">0.25&#8211;0.74</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.36</td><td char="." align="char">0.005</td><td align="left">0.36</td><td char="&#8211;" align="char">0.18&#8211;0.73</td></tr><tr><td align="left">&#160;DRB1*0804<sup>b</sup></td><td char="." align="char">20</td><td char="&#177;" align="char">1.37&#160;&#177;&#160;0.49</td><td char="." align="char">0.006</td><td char="." align="char">3.93</td><td char="&#8211;" align="char">1.50&#8211;10.31</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr></tbody>
###xml 1098 1521 1090 1489 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Alternative multivariable model 1<sup>a</sup></th><th align="left" colspan="4">Alternative multivariable model 2<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">OR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">HIV-1 infection</td><td char="." align="char">228</td><td char="&#177;" align="char">&#8722;0.44&#160;&#177;&#160;0.17</td><td char="." align="char">0.010</td><td char="." align="char">0.42</td><td char="&#8211;" align="char">0.22&#8211;0.81</td><td align="left">&#8722;0.73&#160;&#177;&#160;0.31</td><td char="." align="char">0.021</td><td align="left">0.23</td><td char="&#8211;" align="char">0.07&#8211;0.80</td></tr><tr><td align="left" colspan="10">HLA variants</td></tr><tr><td align="left">&#160;DRB1*03</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.78&#160;&#177;&#160;0.28</td><td char="." align="char">0.006</td><td char="." align="char">0.46</td><td char="&#8211;" align="char">0.26&#8211;0.80</td><td align="left">&#8722;0.88&#160;&#177;&#160;0.35</td><td char="." align="char">0.013</td><td align="left">0.42</td><td char="&#8211;" align="char">0.21&#8211;0.83</td></tr><tr><td align="left">&#160;DRB1*0701</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.84&#160;&#177;&#160;0.28</td><td char="." align="char">0.002</td><td char="." align="char">0.43</td><td char="&#8211;" align="char">0.25&#8211;0.74</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.36</td><td char="." align="char">0.005</td><td align="left">0.36</td><td char="&#8211;" align="char">0.18&#8211;0.73</td></tr><tr><td align="left">&#160;DRB1*0804<sup>b</sup></td><td char="." align="char">20</td><td char="&#177;" align="char">1.37&#160;&#177;&#160;0.49</td><td char="." align="char">0.006</td><td char="." align="char">3.93</td><td char="&#8211;" align="char">1.50&#8211;10.31</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr></tbody></table>
###xml 1521 1522 1489 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1580 1581 1548 1549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1521 1900 1489 1867 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46"><sup>a</sup>These analyses are restricted to 308 patients, when 27 HIV<sup>+</sup> patients with severe immunodeficiency (&lt;200 CD4+ T cells/&#956;L) are excluded. First model tests three ordered groups of patients (HR, MR, and NR), while the second tests two patient groups, i.e. (HR&#160;+&#160;MR) versus NR. In both models, age, ethnicity, and sex are treated as additional covariates for statistical adjustments</p>
###xml 1900 1901 1867 1868 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1982 1984 1949 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 1900 1999 1867 1966 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><sup>b</sup>DRB1*0804 is not suited for model 2 as it is only found in responders (HR&#160;+&#160;MR); <italic>NA</italic> not applicable</p>
###xml 1521 1999 1489 1966 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46"><sup>a</sup>These analyses are restricted to 308 patients, when 27 HIV<sup>+</sup> patients with severe immunodeficiency (&lt;200 CD4+ T cells/&#956;L) are excluded. First model tests three ordered groups of patients (HR, MR, and NR), while the second tests two patient groups, i.e. (HR&#160;+&#160;MR) versus NR. In both models, age, ethnicity, and sex are treated as additional covariates for statistical adjustments</p><p textid="47"><sup>b</sup>DRB1*0804 is not suited for model 2 as it is only found in responders (HR&#160;+&#160;MR); <italic>NA</italic> not applicable</p></table-wrap-foot>
###xml 994 1999 986 1966 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="45">Additional multivariable models to facilitate direct comparison with some of the earlier findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Alternative multivariable model 1<sup>a</sup></th><th align="left" colspan="4">Alternative multivariable model 2<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">OR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">HIV-1 infection</td><td char="." align="char">228</td><td char="&#177;" align="char">&#8722;0.44&#160;&#177;&#160;0.17</td><td char="." align="char">0.010</td><td char="." align="char">0.42</td><td char="&#8211;" align="char">0.22&#8211;0.81</td><td align="left">&#8722;0.73&#160;&#177;&#160;0.31</td><td char="." align="char">0.021</td><td align="left">0.23</td><td char="&#8211;" align="char">0.07&#8211;0.80</td></tr><tr><td align="left" colspan="10">HLA variants</td></tr><tr><td align="left">&#160;DRB1*03</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.78&#160;&#177;&#160;0.28</td><td char="." align="char">0.006</td><td char="." align="char">0.46</td><td char="&#8211;" align="char">0.26&#8211;0.80</td><td align="left">&#8722;0.88&#160;&#177;&#160;0.35</td><td char="." align="char">0.013</td><td align="left">0.42</td><td char="&#8211;" align="char">0.21&#8211;0.83</td></tr><tr><td align="left">&#160;DRB1*0701</td><td char="." align="char">67</td><td char="&#177;" align="char">&#8722;0.84&#160;&#177;&#160;0.28</td><td char="." align="char">0.002</td><td char="." align="char">0.43</td><td char="&#8211;" align="char">0.25&#8211;0.74</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.36</td><td char="." align="char">0.005</td><td align="left">0.36</td><td char="&#8211;" align="char">0.18&#8211;0.73</td></tr><tr><td align="left">&#160;DRB1*0804<sup>b</sup></td><td char="." align="char">20</td><td char="&#177;" align="char">1.37&#160;&#177;&#160;0.49</td><td char="." align="char">0.006</td><td char="." align="char">3.93</td><td char="&#8211;" align="char">1.50&#8211;10.31</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr></tbody></table><table-wrap-foot><p textid="46"><sup>a</sup>These analyses are restricted to 308 patients, when 27 HIV<sup>+</sup> patients with severe immunodeficiency (&lt;200 CD4+ T cells/&#956;L) are excluded. First model tests three ordered groups of patients (HR, MR, and NR), while the second tests two patient groups, i.e. (HR&#160;+&#160;MR) versus NR. In both models, age, ethnicity, and sex are treated as additional covariates for statistical adjustments</p><p textid="47"><sup>b</sup>DRB1*0804 is not suited for model 2 as it is only found in responders (HR&#160;+&#160;MR); <italic>NA</italic> not applicable</p></table-wrap-foot></table-wrap>
###xml 120 123 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 428 433 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1559 1567 <span type="species:ncbi:9606">patients</span>
###xml 1577 1580 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1582 1590 <span type="species:ncbi:9606">patients</span>
###xml 1700 1708 <span type="species:ncbi:9606">patients</span>
###xml 1754 1761 <span type="species:ncbi:9606">patient</span>
To facilitate direct comparison with earlier findings based on vaccine recipients without apparent immunodeficiency, 27 HIV+ subjects with severe immunodeficiency (<200 CD4+ T cells/muL) were excluded from the testing of an alternative model (Table 3). DRB1*03, DRB1*0701, and DRB1*0804 remained as cofactors associated with differential Ab responses (P = 0.002-0.006), even after statistical adjustment for residual effects of HIV-1 infection and other non-genetic factors. A second alternative model used the strategy tested in another cohort of youth (Wang et al. 2004), when responders were not further differentiated into HR and MR groups. Again, DRB1*03 and *0701 were independently associated with differential Ab response status (Table 3), with similar parameter estimates (beta = -0.88 +/- 0.35 and -1.03 +/- 0.36, P = 0.013 and 0.005, respectively). The effect of DRB1*0804 could not be reliably established, as the allele was only present in the aggregated responder group (HR + MR).Table 3Additional multivariable models to facilitate direct comparison with some of the earlier findingsFactors (covariates)nAlternative multivariable model 1aAlternative multivariable model 2abeta +/- SEPpOR95% CIbeta +/- SEPOR95% CIHIV-1 infection228-0.44 +/- 0.170.0100.420.22-0.81-0.73 +/- 0.310.0210.230.07-0.80HLA variants DRB1*0367-0.78 +/- 0.280.0060.460.26-0.80-0.88 +/- 0.350.0130.420.21-0.83 DRB1*070167-0.84 +/- 0.280.0020.430.25-0.74-1.03 +/- 0.360.0050.360.18-0.73 DRB1*0804b201.37 +/- 0.490.0063.931.50-10.31NANAaThese analyses are restricted to 308 patients, when 27 HIV+ patients with severe immunodeficiency (<200 CD4+ T cells/muL) are excluded. First model tests three ordered groups of patients (HR, MR, and NR), while the second tests two patient groups, i.e. (HR + MR) versus NR. In both models, age, ethnicity, and sex are treated as additional covariates for statistical adjustmentsbDRB1*0804 is not suited for model 2 as it is only found in responders (HR + MR); NA not applicable
###end p 44
###begin p 45
Additional multivariable models to facilitate direct comparison with some of the earlier findings
###end p 45
###begin p 46
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 233 240 <span type="species:ncbi:9606">patient</span>
aThese analyses are restricted to 308 patients, when 27 HIV+ patients with severe immunodeficiency (<200 CD4+ T cells/muL) are excluded. First model tests three ordered groups of patients (HR, MR, and NR), while the second tests two patient groups, i.e. (HR + MR) versus NR. In both models, age, ethnicity, and sex are treated as additional covariates for statistical adjustments
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 82 84 82 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
bDRB1*0804 is not suited for model 2 as it is only found in responders (HR + MR); NA not applicable
###end p 47
###begin title 48
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Analyses restricted to 255 HIV+ subjects
###end title 48
###begin p 49
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 259 260 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 304 305 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 312 313 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 351 352 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 359 360 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 385 386 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 393 394 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 420 424 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 444 445 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 452 453 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 476 477 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 484 485 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 725 726 723 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 880 881 878 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 938 939 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1044 1052 1042 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 1080 1087 1078 1085 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 1135 1136 1133 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1087 1143 1085 1141 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">Analyses confined to 255 HIV-1 seropositive (HIV<sup>+</sup>) youth</p>
###xml 1087 1143 1085 1141 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50">Analyses confined to 255 HIV-1 seropositive (HIV<sup>+</sup>) youth</p></caption>
###xml 1143 1174 1141 1172 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Individual factors (covariates)</th>
###xml 1174 1175 1172 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1174 1175 1172 1173 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>n</italic></th>
###xml 1210 1211 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1175 1211 1173 1209 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Parameters from univariate analyses<sup>a</sup></th>
###xml 1238 1239 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1211 1239 1209 1237 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Reduced multivariable model<sup>a</sup></th>
###xml 1143 1239 1141 1237 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Parameters from univariate analyses<sup>a</sup></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr>
###xml 1239 1243 1237 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1239 1250 1237 1243 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1250 1251 1243 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1250 1251 1243 1244 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1251 1254 1244 1247 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 1254 1260 1247 1253 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1260 1264 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1260 1271 1253 1259 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 1271 1272 1259 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1271 1272 1259 1260 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1272 1275 1260 1263 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 1275 1281 1263 1269 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 1239 1281 1237 1269 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr>
###xml 1143 1281 1141 1269 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Parameters from univariate analyses<sup>a</sup></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead>
###xml 1302 1303 1289 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1281 1303 1269 1290 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&lt;200 CD4+ T cells/&#956;L<sup>b</sup></td>
###xml 1303 1305 1290 1292 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27</td>
###xml 1305 1319 1292 1304 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;2.69&#160;&#177;&#160;0.48</td>
###xml 1319 1326 1304 1311 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1326 1330 1311 1315 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.07</td>
###xml 1330 1339 1315 1324 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.03&#8211;0.18</td>
###xml 1339 1353 1324 1336 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;2.95&#160;&#177;&#160;0.50</td>
###xml 1353 1360 1336 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1360 1364 1343 1347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.06</td>
###xml 1364 1373 1347 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.02&#8211;0.14</td>
###xml 1281 1373 1269 1356 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&lt;200 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">27</td><td char="&#177;" align="char">&#8722;2.69&#160;&#177;&#160;0.48</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.07</td><td char="&#8211;" align="char">0.03&#8211;0.18</td><td align="left">&#8722;2.95&#160;&#177;&#160;0.50</td><td char="." align="char">&lt;0.0001</td><td align="left">0.06</td><td char="&#8211;" align="char">0.02&#8211;0.14</td></tr>
###xml 1397 1398 1379 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1373 1398 1356 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">200&#8211;450 CD4+ T cells/&#956;L<sup>b</sup></td>
###xml 1398 1400 1380 1382 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">96</td>
###xml 1400 1414 1382 1394 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;1.01&#160;&#177;&#160;0.26</td>
###xml 1414 1420 1394 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1420 1424 1400 1404 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.36</td>
###xml 1424 1433 1404 1413 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.22&#8211;0.61</td>
###xml 1433 1447 1413 1425 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;1.03&#160;&#177;&#160;0.27</td>
###xml 1447 1453 1425 1431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1453 1457 1431 1435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.36</td>
###xml 1457 1466 1435 1444 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.21&#8211;0.61</td>
###xml 1373 1466 1356 1444 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">200&#8211;450 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">96</td><td char="&#177;" align="char">&#8722;1.01&#160;&#177;&#160;0.26</td><td char="." align="char">&lt;0.001</td><td char="." align="char">0.36</td><td char="&#8211;" align="char">0.22&#8211;0.61</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.27</td><td char="." align="char">&lt;0.001</td><td align="left">0.36</td><td char="&#8211;" align="char">0.21&#8211;0.61</td></tr>
###xml 1489 1490 1467 1468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1466 1490 1444 1468 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="10">Individual HLA variants<sup>c</sup></td>
###xml 1466 1490 1444 1468 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="10">Individual HLA variants<sup>c</sup></td></tr>
###xml 1490 1498 1468 1476 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*03</td>
###xml 1498 1500 1476 1478 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">58</td>
###xml 1500 1514 1478 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.58&#160;&#177;&#160;0.28</td>
###xml 1514 1519 1490 1495 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.039</td>
###xml 1519 1523 1495 1499 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.56</td>
###xml 1523 1532 1499 1508 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.32&#8211;0.97</td>
###xml 1532 1546 1508 1520 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.67&#160;&#177;&#160;0.31</td>
###xml 1546 1551 1520 1525 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.029</td>
###xml 1551 1555 1525 1529 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.51</td>
###xml 1555 1564 1529 1538 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.28&#8211;0.93</td>
###xml 1490 1564 1468 1538 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*03</td><td char="." align="char">58</td><td char="&#177;" align="char">&#8722;0.58&#160;&#177;&#160;0.28</td><td char="." align="char">0.039</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.32&#8211;0.97</td><td align="left">&#8722;0.67&#160;&#177;&#160;0.31</td><td char="." align="char">0.029</td><td align="left">0.51</td><td char="&#8211;" align="char">0.28&#8211;0.93</td></tr>
###xml 1564 1572 1538 1546 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*04</td>
###xml 1572 1574 1546 1548 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">44</td>
###xml 1574 1588 1548 1560 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.61&#160;&#177;&#160;0.31</td>
###xml 1588 1593 1560 1565 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.054</td>
###xml 1593 1597 1565 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.55</td>
###xml 1597 1606 1569 1578 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.35&#8211;1.01</td>
###xml 1606 1608 1578 1580 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1608 1608 1580 1580 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1608 1610 1580 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1610 1610 1582 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1564 1610 1538 1582 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*04</td><td char="." align="char">44</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.31</td><td char="." align="char">0.054</td><td char="." align="char">0.55</td><td char="&#8211;" align="char">0.35&#8211;1.01</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr>
###xml 1610 1620 1582 1592 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*0701</td>
###xml 1620 1622 1592 1594 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">56</td>
###xml 1622 1636 1594 1606 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.40&#160;&#177;&#160;0.28</td>
###xml 1636 1641 1606 1611 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.159</td>
###xml 1641 1645 1611 1615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.67</td>
###xml 1645 1654 1615 1624 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.38&#8211;1.17</td>
###xml 1654 1668 1624 1636 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.68&#160;&#177;&#160;0.31</td>
###xml 1668 1673 1636 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 1673 1677 1641 1645 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.50</td>
###xml 1677 1686 1645 1654 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.28&#8211;0.92</td>
###xml 1610 1686 1582 1654 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*0701</td><td char="." align="char">56</td><td char="&#177;" align="char">&#8722;0.40&#160;&#177;&#160;0.28</td><td char="." align="char">0.159</td><td char="." align="char">0.67</td><td char="&#8211;" align="char">0.38&#8211;1.17</td><td align="left">&#8722;0.68&#160;&#177;&#160;0.31</td><td char="." align="char">0.026</td><td align="left">0.50</td><td char="&#8211;" align="char">0.28&#8211;0.92</td></tr>
###xml 1686 1696 1654 1664 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*0804</td>
###xml 1696 1698 1664 1666 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">18</td>
###xml 1698 1711 1666 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.40&#160;&#177;&#160;0.48</td>
###xml 1711 1716 1677 1682 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.003</td>
###xml 1716 1720 1682 1686 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.06</td>
###xml 1720 1730 1686 1696 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.59&#8211;10.34</td>
###xml 1730 1743 1696 1707 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.44&#160;&#177;&#160;0.51</td>
###xml 1743 1748 1707 1712 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.005</td>
###xml 1748 1752 1712 1716 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.23</td>
###xml 1752 1762 1716 1726 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.55&#8211;11.58</td>
###xml 1686 1762 1654 1726 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*0804</td><td char="." align="char">18</td><td char="&#177;" align="char">1.40&#160;&#177;&#160;0.48</td><td char="." align="char">0.003</td><td char="." align="char">4.06</td><td char="&#8211;" align="char">1.59&#8211;10.34</td><td align="left">1.44&#160;&#177;&#160;0.51</td><td char="." align="char">0.005</td><td align="left">4.23</td><td char="&#8211;" align="char">1.55&#8211;11.58</td></tr>
###xml 1770 1771 1734 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1762 1771 1726 1735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*15<sup>d</sup></td>
###xml 1771 1773 1735 1737 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">55</td>
###xml 1773 1786 1737 1748 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.49&#160;&#177;&#160;0.29</td>
###xml 1786 1791 1748 1753 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.092</td>
###xml 1791 1795 1753 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.62</td>
###xml 1795 1804 1757 1766 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.93&#8211;2.85</td>
###xml 1804 1806 1766 1768 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1806 1806 1768 1768 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1806 1808 1768 1770 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1808 1808 1770 1770 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1762 1808 1726 1770 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*15<sup>d</sup></td><td char="." align="char">55</td><td char="&#177;" align="char">0.49&#160;&#177;&#160;0.29</td><td char="." align="char">0.092</td><td char="." align="char">1.62</td><td char="&#8211;" align="char">0.93&#8211;2.85</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr>
###xml 1281 1808 1269 1770 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">&lt;200 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">27</td><td char="&#177;" align="char">&#8722;2.69&#160;&#177;&#160;0.48</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.07</td><td char="&#8211;" align="char">0.03&#8211;0.18</td><td align="left">&#8722;2.95&#160;&#177;&#160;0.50</td><td char="." align="char">&lt;0.0001</td><td align="left">0.06</td><td char="&#8211;" align="char">0.02&#8211;0.14</td></tr><tr><td align="left">200&#8211;450 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">96</td><td char="&#177;" align="char">&#8722;1.01&#160;&#177;&#160;0.26</td><td char="." align="char">&lt;0.001</td><td char="." align="char">0.36</td><td char="&#8211;" align="char">0.22&#8211;0.61</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.27</td><td char="." align="char">&lt;0.001</td><td align="left">0.36</td><td char="&#8211;" align="char">0.21&#8211;0.61</td></tr><tr><td align="left" colspan="10">Individual HLA variants<sup>c</sup></td></tr><tr><td align="left">&#160;DRB1*03</td><td char="." align="char">58</td><td char="&#177;" align="char">&#8722;0.58&#160;&#177;&#160;0.28</td><td char="." align="char">0.039</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.32&#8211;0.97</td><td align="left">&#8722;0.67&#160;&#177;&#160;0.31</td><td char="." align="char">0.029</td><td align="left">0.51</td><td char="&#8211;" align="char">0.28&#8211;0.93</td></tr><tr><td align="left">&#160;DRB1*04</td><td char="." align="char">44</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.31</td><td char="." align="char">0.054</td><td char="." align="char">0.55</td><td char="&#8211;" align="char">0.35&#8211;1.01</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr><tr><td align="left">&#160;DRB1*0701</td><td char="." align="char">56</td><td char="&#177;" align="char">&#8722;0.40&#160;&#177;&#160;0.28</td><td char="." align="char">0.159</td><td char="." align="char">0.67</td><td char="&#8211;" align="char">0.38&#8211;1.17</td><td align="left">&#8722;0.68&#160;&#177;&#160;0.31</td><td char="." align="char">0.026</td><td align="left">0.50</td><td char="&#8211;" align="char">0.28&#8211;0.92</td></tr><tr><td align="left">&#160;DRB1*0804</td><td char="." align="char">18</td><td char="&#177;" align="char">1.40&#160;&#177;&#160;0.48</td><td char="." align="char">0.003</td><td char="." align="char">4.06</td><td char="&#8211;" align="char">1.59&#8211;10.34</td><td align="left">1.44&#160;&#177;&#160;0.51</td><td char="." align="char">0.005</td><td align="left">4.23</td><td char="&#8211;" align="char">1.55&#8211;11.58</td></tr><tr><td align="left">&#160;DRB1*15<sup>d</sup></td><td char="." align="char">55</td><td char="&#177;" align="char">0.49&#160;&#177;&#160;0.29</td><td char="." align="char">0.092</td><td char="." align="char">1.62</td><td char="&#8211;" align="char">0.93&#8211;2.85</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr></tbody>
###xml 1143 1808 1141 1770 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Parameters from univariate analyses<sup>a</sup></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">&lt;200 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">27</td><td char="&#177;" align="char">&#8722;2.69&#160;&#177;&#160;0.48</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.07</td><td char="&#8211;" align="char">0.03&#8211;0.18</td><td align="left">&#8722;2.95&#160;&#177;&#160;0.50</td><td char="." align="char">&lt;0.0001</td><td align="left">0.06</td><td char="&#8211;" align="char">0.02&#8211;0.14</td></tr><tr><td align="left">200&#8211;450 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">96</td><td char="&#177;" align="char">&#8722;1.01&#160;&#177;&#160;0.26</td><td char="." align="char">&lt;0.001</td><td char="." align="char">0.36</td><td char="&#8211;" align="char">0.22&#8211;0.61</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.27</td><td char="." align="char">&lt;0.001</td><td align="left">0.36</td><td char="&#8211;" align="char">0.21&#8211;0.61</td></tr><tr><td align="left" colspan="10">Individual HLA variants<sup>c</sup></td></tr><tr><td align="left">&#160;DRB1*03</td><td char="." align="char">58</td><td char="&#177;" align="char">&#8722;0.58&#160;&#177;&#160;0.28</td><td char="." align="char">0.039</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.32&#8211;0.97</td><td align="left">&#8722;0.67&#160;&#177;&#160;0.31</td><td char="." align="char">0.029</td><td align="left">0.51</td><td char="&#8211;" align="char">0.28&#8211;0.93</td></tr><tr><td align="left">&#160;DRB1*04</td><td char="." align="char">44</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.31</td><td char="." align="char">0.054</td><td char="." align="char">0.55</td><td char="&#8211;" align="char">0.35&#8211;1.01</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr><tr><td align="left">&#160;DRB1*0701</td><td char="." align="char">56</td><td char="&#177;" align="char">&#8722;0.40&#160;&#177;&#160;0.28</td><td char="." align="char">0.159</td><td char="." align="char">0.67</td><td char="&#8211;" align="char">0.38&#8211;1.17</td><td align="left">&#8722;0.68&#160;&#177;&#160;0.31</td><td char="." align="char">0.026</td><td align="left">0.50</td><td char="&#8211;" align="char">0.28&#8211;0.92</td></tr><tr><td align="left">&#160;DRB1*0804</td><td char="." align="char">18</td><td char="&#177;" align="char">1.40&#160;&#177;&#160;0.48</td><td char="." align="char">0.003</td><td char="." align="char">4.06</td><td char="&#8211;" align="char">1.59&#8211;10.34</td><td align="left">1.44&#160;&#177;&#160;0.51</td><td char="." align="char">0.005</td><td align="left">4.23</td><td char="&#8211;" align="char">1.55&#8211;11.58</td></tr><tr><td align="left">&#160;DRB1*15<sup>d</sup></td><td char="." align="char">55</td><td char="&#177;" align="char">0.49&#160;&#177;&#160;0.29</td><td char="." align="char">0.092</td><td char="." align="char">1.62</td><td char="&#8211;" align="char">0.93&#8211;2.85</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr></tbody></table>
###xml 1808 1809 1770 1771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2059 2061 2021 2023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 2087 2088 2049 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1808 2097 1770 2059 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51"><sup>a</sup>Univariate analyses correspond to tests for trend across three patient groups (HR, MR, and NR), while multivariable model highlights all independent factors (with further statistical adjustments for potential confounding by age, ethnicity, and sex). <italic>NA</italic> not applicable (adjusted <italic>P</italic>&#160;&gt;&#160;0.050)</p>
###xml 2097 2098 2059 2060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2097 2214 2059 2175 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52"><sup>b</sup>As measured at baseline (time of enrollment). Patients with &gt;450 CD4+ T cell counts/&#956;L serve as the reference group</p>
###xml 2214 2215 2175 2176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2214 2284 2175 2245 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53"><sup>c</sup>Other variants are dismissed by univariate and multivariable analyses</p>
###xml 2284 2285 2245 2246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 2284 2362 2245 2323 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54"><sup>d</sup>In these 55 patients, DRB1*15&#8211;DQB1*06 is the only haplotype involving DRB1*15</p>
###xml 1808 2362 1770 2323 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51"><sup>a</sup>Univariate analyses correspond to tests for trend across three patient groups (HR, MR, and NR), while multivariable model highlights all independent factors (with further statistical adjustments for potential confounding by age, ethnicity, and sex). <italic>NA</italic> not applicable (adjusted <italic>P</italic>&#160;&gt;&#160;0.050)</p><p textid="52"><sup>b</sup>As measured at baseline (time of enrollment). Patients with &gt;450 CD4+ T cell counts/&#956;L serve as the reference group</p><p textid="53"><sup>c</sup>Other variants are dismissed by univariate and multivariable analyses</p><p textid="54"><sup>d</sup>In these 55 patients, DRB1*15&#8211;DQB1*06 is the only haplotype involving DRB1*15</p></table-wrap-foot>
###xml 1080 2362 1078 2323 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="50">Analyses confined to 255 HIV-1 seropositive (HIV<sup>+</sup>) youth</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Parameters from univariate analyses<sup>a</sup></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">&lt;200 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">27</td><td char="&#177;" align="char">&#8722;2.69&#160;&#177;&#160;0.48</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.07</td><td char="&#8211;" align="char">0.03&#8211;0.18</td><td align="left">&#8722;2.95&#160;&#177;&#160;0.50</td><td char="." align="char">&lt;0.0001</td><td align="left">0.06</td><td char="&#8211;" align="char">0.02&#8211;0.14</td></tr><tr><td align="left">200&#8211;450 CD4+ T cells/&#956;L<sup>b</sup></td><td char="." align="char">96</td><td char="&#177;" align="char">&#8722;1.01&#160;&#177;&#160;0.26</td><td char="." align="char">&lt;0.001</td><td char="." align="char">0.36</td><td char="&#8211;" align="char">0.22&#8211;0.61</td><td align="left">&#8722;1.03&#160;&#177;&#160;0.27</td><td char="." align="char">&lt;0.001</td><td align="left">0.36</td><td char="&#8211;" align="char">0.21&#8211;0.61</td></tr><tr><td align="left" colspan="10">Individual HLA variants<sup>c</sup></td></tr><tr><td align="left">&#160;DRB1*03</td><td char="." align="char">58</td><td char="&#177;" align="char">&#8722;0.58&#160;&#177;&#160;0.28</td><td char="." align="char">0.039</td><td char="." align="char">0.56</td><td char="&#8211;" align="char">0.32&#8211;0.97</td><td align="left">&#8722;0.67&#160;&#177;&#160;0.31</td><td char="." align="char">0.029</td><td align="left">0.51</td><td char="&#8211;" align="char">0.28&#8211;0.93</td></tr><tr><td align="left">&#160;DRB1*04</td><td char="." align="char">44</td><td char="&#177;" align="char">&#8722;0.61&#160;&#177;&#160;0.31</td><td char="." align="char">0.054</td><td char="." align="char">0.55</td><td char="&#8211;" align="char">0.35&#8211;1.01</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr><tr><td align="left">&#160;DRB1*0701</td><td char="." align="char">56</td><td char="&#177;" align="char">&#8722;0.40&#160;&#177;&#160;0.28</td><td char="." align="char">0.159</td><td char="." align="char">0.67</td><td char="&#8211;" align="char">0.38&#8211;1.17</td><td align="left">&#8722;0.68&#160;&#177;&#160;0.31</td><td char="." align="char">0.026</td><td align="left">0.50</td><td char="&#8211;" align="char">0.28&#8211;0.92</td></tr><tr><td align="left">&#160;DRB1*0804</td><td char="." align="char">18</td><td char="&#177;" align="char">1.40&#160;&#177;&#160;0.48</td><td char="." align="char">0.003</td><td char="." align="char">4.06</td><td char="&#8211;" align="char">1.59&#8211;10.34</td><td align="left">1.44&#160;&#177;&#160;0.51</td><td char="." align="char">0.005</td><td align="left">4.23</td><td char="&#8211;" align="char">1.55&#8211;11.58</td></tr><tr><td align="left">&#160;DRB1*15<sup>d</sup></td><td char="." align="char">55</td><td char="&#177;" align="char">0.49&#160;&#177;&#160;0.29</td><td char="." align="char">0.092</td><td char="." align="char">1.62</td><td char="&#8211;" align="char">0.93&#8211;2.85</td><td align="left">NA</td><td align="left"/><td align="left">NA</td><td align="left"/></tr></tbody></table><table-wrap-foot><p textid="51"><sup>a</sup>Univariate analyses correspond to tests for trend across three patient groups (HR, MR, and NR), while multivariable model highlights all independent factors (with further statistical adjustments for potential confounding by age, ethnicity, and sex). <italic>NA</italic> not applicable (adjusted <italic>P</italic>&#160;&gt;&#160;0.050)</p><p textid="52"><sup>b</sup>As measured at baseline (time of enrollment). Patients with &gt;450 CD4+ T cell counts/&#956;L serve as the reference group</p><p textid="53"><sup>c</sup>Other variants are dismissed by univariate and multivariable analyses</p><p textid="54"><sup>d</sup>In these 55 patients, DRB1*15&#8211;DQB1*06 is the only haplotype involving DRB1*15</p></table-wrap-foot></table-wrap>
###xml 50 53 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 908 913 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1112 1117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1132 1135 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1872 1879 <span type="species:ncbi:9606">patient</span>
###xml 2144 2152 <span type="species:ncbi:9606">Patients</span>
###xml 2297 2305 <span type="species:ncbi:9606">patients</span>
Stepwise analyses were further applied to the 255 HIV+ individuals alone (Table 4). By univariate analyses, severe immunodeficiency (<200 CD4+ T cells/muL) and moderate immunodeficiency (200-450 CD4+ T cells/muL) had a strong negative impact on Ab responses (P < 0.001). DRB1*0701 became a minor factor (n = 56, P = 0.159) when compared with DRB1*03 (n = 58, P = 0.039) and DRB1*0804 (n = 18, P = 0.003). Two additional DRB1 variants, DRB1*04 (n = 44, P = 0.054) and DRB1*15 (n = 55, P = 0.092), were recognized as marginally unfavorable and favorable, respectively, with the latter found exclusively on the DRB1*15-DQB1*06 haplotype. Only DRB1*03, DRB1*0701, and DRB1*0804 could be retained as independent factors (adjusted P = 0.005-0.029) in the reduced multivariable model, after statistical adjustments for the clear, negative impact of severe and moderate immunodeficiency (P < 0.001). Thus, replacing HIV-1 infection status (Table 2) with CD4+ T cell count as a key non-genetic factor did not alter the independent associations of three HLA-DRB1 variants with Ab responses.Table 4Analyses confined to 255 HIV-1 seropositive (HIV+) youthIndividual factors (covariates)nParameters from univariate analysesaReduced multivariable modelabeta +/- SEPpOR95% CIbeta +/- SEPpOR95% CI<200 CD4+ T cells/muLb27-2.69 +/- 0.48<0.00010.070.03-0.18-2.95 +/- 0.50<0.00010.060.02-0.14200-450 CD4+ T cells/muLb96-1.01 +/- 0.26<0.0010.360.22-0.61-1.03 +/- 0.27<0.0010.360.21-0.61Individual HLA variantsc DRB1*0358-0.58 +/- 0.280.0390.560.32-0.97-0.67 +/- 0.310.0290.510.28-0.93 DRB1*0444-0.61 +/- 0.310.0540.550.35-1.01NANA DRB1*070156-0.40 +/- 0.280.1590.670.38-1.17-0.68 +/- 0.310.0260.500.28-0.92 DRB1*0804181.40 +/- 0.480.0034.061.59-10.341.44 +/- 0.510.0054.231.55-11.58 DRB1*15d550.49 +/- 0.290.0921.620.93-2.85NANAaUnivariate analyses correspond to tests for trend across three patient groups (HR, MR, and NR), while multivariable model highlights all independent factors (with further statistical adjustments for potential confounding by age, ethnicity, and sex). NA not applicable (adjusted P > 0.050)bAs measured at baseline (time of enrollment). Patients with >450 CD4+ T cell counts/muL serve as the reference groupcOther variants are dismissed by univariate and multivariable analysesdIn these 55 patients, DRB1*15-DQB1*06 is the only haplotype involving DRB1*15
###end p 49
###begin p 50
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Analyses confined to 255 HIV-1 seropositive (HIV+) youth
###end p 50
###begin p 51
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 251 253 251 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 64 71 <span type="species:ncbi:9606">patient</span>
aUnivariate analyses correspond to tests for trend across three patient groups (HR, MR, and NR), while multivariable model highlights all independent factors (with further statistical adjustments for potential confounding by age, ethnicity, and sex). NA not applicable (adjusted P > 0.050)
###end p 51
###begin p 52
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 47 55 <span type="species:ncbi:9606">Patients</span>
bAs measured at baseline (time of enrollment). Patients with >450 CD4+ T cell counts/muL serve as the reference group
###end p 52
###begin p 53
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cOther variants are dismissed by univariate and multivariable analyses
###end p 53
###begin p 54
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
dIn these 55 patients, DRB1*15-DQB1*06 is the only haplotype involving DRB1*15
###end p 54
###begin title 55
Analyses confined to 229 Hispanic subjects
###end title 55
###begin p 56
###xml 53 54 53 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab5" ref-type="table">5</xref>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 478 485 478 485 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;5</label>
###xml 485 538 485 538 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="57">Multivariable analyses confined to 229 Hispanic youth</p>
###xml 485 538 485 538 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="57">Multivariable analyses confined to 229 Hispanic youth</p></caption>
###xml 538 569 538 569 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Individual factors (covariates)</th>
###xml 569 570 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 569 570 569 570 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>n</italic></th>
###xml 597 598 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 570 598 570 598 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Reduced multivariable model<sup>a</sup></th>
###xml 538 598 538 598 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr>
###xml 598 602 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 598 609 598 604 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th>
###xml 609 610 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 609 610 604 605 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 610 613 605 608 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pOR</th>
###xml 613 619 608 614 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 598 619 598 614 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr>
###xml 538 619 538 614 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead>
###xml 619 634 614 629 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HIV-1 infection</td>
###xml 634 637 629 632 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">169</td>
###xml 637 651 632 644 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">&#8722;0.83&#160;&#177;&#160;0.21</td>
###xml 651 658 644 651 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 658 662 651 655 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.19</td>
###xml 662 671 655 664 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.08&#8211;0.43</td>
###xml 619 671 614 664 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HIV-1 infection</td><td char="." align="char">169</td><td char="&#177;" align="char">&#8722;0.83&#160;&#177;&#160;0.21</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.19</td><td char="&#8211;" align="char">0.08&#8211;0.43</td></tr>
###xml 694 695 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 671 695 664 688 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">Individual HLA variants<sup>b</sup></td>
###xml 671 695 664 688 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">Individual HLA variants<sup>b</sup></td></tr>
###xml 695 705 688 698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*0804</td>
###xml 705 707 698 700 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 707 720 700 711 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.26&#160;&#177;&#160;0.63</td>
###xml 720 725 711 716 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.045</td>
###xml 725 729 716 720 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.53</td>
###xml 729 739 720 730 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.03&#8211;12.06</td>
###xml 695 739 688 730 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*0804</td><td char="." align="char">11</td><td char="&#177;" align="char">1.26&#160;&#177;&#160;0.63</td><td char="." align="char">0.045</td><td char="." align="char">3.53</td><td char="&#8211;" align="char">1.03&#8211;12.06</td></tr>
###xml 739 747 730 738 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DRB1*15</td>
###xml 747 749 738 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">47</td>
###xml 749 762 740 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.77&#160;&#177;&#160;0.33</td>
###xml 762 767 751 756 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.019</td>
###xml 767 771 756 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.16</td>
###xml 771 780 760 769 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">1.13&#8211;4.10</td>
###xml 739 780 730 769 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DRB1*15</td><td char="." align="char">47</td><td char="&#177;" align="char">0.77&#160;&#177;&#160;0.33</td><td char="." align="char">0.019</td><td char="." align="char">2.16</td><td char="&#8211;" align="char">1.13&#8211;4.10</td></tr>
###xml 619 780 614 769 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">HIV-1 infection</td><td char="." align="char">169</td><td char="&#177;" align="char">&#8722;0.83&#160;&#177;&#160;0.21</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.19</td><td char="&#8211;" align="char">0.08&#8211;0.43</td></tr><tr><td align="left" colspan="6">Individual HLA variants<sup>b</sup></td></tr><tr><td align="left">&#160;DRB1*0804</td><td char="." align="char">11</td><td char="&#177;" align="char">1.26&#160;&#177;&#160;0.63</td><td char="." align="char">0.045</td><td char="." align="char">3.53</td><td char="&#8211;" align="char">1.03&#8211;12.06</td></tr><tr><td align="left">&#160;DRB1*15</td><td char="." align="char">47</td><td char="&#177;" align="char">0.77&#160;&#177;&#160;0.33</td><td char="." align="char">0.019</td><td char="." align="char">2.16</td><td char="&#8211;" align="char">1.13&#8211;4.10</td></tr></tbody>
###xml 538 780 538 769 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">HIV-1 infection</td><td char="." align="char">169</td><td char="&#177;" align="char">&#8722;0.83&#160;&#177;&#160;0.21</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.19</td><td char="&#8211;" align="char">0.08&#8211;0.43</td></tr><tr><td align="left" colspan="6">Individual HLA variants<sup>b</sup></td></tr><tr><td align="left">&#160;DRB1*0804</td><td char="." align="char">11</td><td char="&#177;" align="char">1.26&#160;&#177;&#160;0.63</td><td char="." align="char">0.045</td><td char="." align="char">3.53</td><td char="&#8211;" align="char">1.03&#8211;12.06</td></tr><tr><td align="left">&#160;DRB1*15</td><td char="." align="char">47</td><td char="&#177;" align="char">0.77&#160;&#177;&#160;0.33</td><td char="." align="char">0.019</td><td char="." align="char">2.16</td><td char="&#8211;" align="char">1.13&#8211;4.10</td></tr></tbody></table>
###xml 780 781 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 825 826 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 780 990 769 979 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="58"><sup>a</sup>Following similar strategies shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>, except that (i) status of HIV-1 infection replaces CD4+ T cell count as the primary non-genetic factor; (ii) only age and sex are treated as additional covariates</p>
###xml 990 991 979 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1068 1069 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 990 1078 979 1067 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="59"><sup>b</sup>Other HLA variants, including DRB1*03 and DRB1*0701, are dismissed (adjusted <italic>P</italic>&#160;&gt;&#160;0.050)</p>
###xml 780 1078 769 1067 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="58"><sup>a</sup>Following similar strategies shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>, except that (i) status of HIV-1 infection replaces CD4+ T cell count as the primary non-genetic factor; (ii) only age and sex are treated as additional covariates</p><p textid="59"><sup>b</sup>Other HLA variants, including DRB1*03 and DRB1*0701, are dismissed (adjusted <italic>P</italic>&#160;&gt;&#160;0.050)</p></table-wrap-foot>
###xml 478 1078 478 1067 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table&#160;5</label><caption><p textid="57">Multivariable analyses confined to 229 Hispanic youth</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Individual factors (covariates)</th><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="4">Reduced multivariable model<sup>a</sup></th></tr><tr><th align="left"><italic>&#946;</italic>&#160;&#177;&#160;SE</th><th align="left"><italic>P</italic></th><th align="left">pOR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">HIV-1 infection</td><td char="." align="char">169</td><td char="&#177;" align="char">&#8722;0.83&#160;&#177;&#160;0.21</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.19</td><td char="&#8211;" align="char">0.08&#8211;0.43</td></tr><tr><td align="left" colspan="6">Individual HLA variants<sup>b</sup></td></tr><tr><td align="left">&#160;DRB1*0804</td><td char="." align="char">11</td><td char="&#177;" align="char">1.26&#160;&#177;&#160;0.63</td><td char="." align="char">0.045</td><td char="." align="char">3.53</td><td char="&#8211;" align="char">1.03&#8211;12.06</td></tr><tr><td align="left">&#160;DRB1*15</td><td char="." align="char">47</td><td char="&#177;" align="char">0.77&#160;&#177;&#160;0.33</td><td char="." align="char">0.019</td><td char="." align="char">2.16</td><td char="&#8211;" align="char">1.13&#8211;4.10</td></tr></tbody></table><table-wrap-foot><p textid="58"><sup>a</sup>Following similar strategies shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>, except that (i) status of HIV-1 infection replaces CD4+ T cell count as the primary non-genetic factor; (ii) only age and sex are treated as additional covariates</p><p textid="59"><sup>b</sup>Other HLA variants, including DRB1*03 and DRB1*0701, are dismissed (adjusted <italic>P</italic>&#160;&gt;&#160;0.050)</p></table-wrap-foot></table-wrap>
###xml 131 136 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 854 859 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In further analyses confined to 229 Hispanics (Table 5), a reduced multivariable model continued to confirm the negative impact of HIV-1 infection on Ab responses (P < 0.0001). DRB1*0804 (n = 11) and DRB1*15 (n = 47) were the only HLA class II variants independently associated with Ab responses (adjusted P = 0.045 and 0.019, respectively). Analyses of other alleles (including DRB1*03 and DRB1*0701) and their haplotypes were inconclusive because of reduced statistical power.Table 5Multivariable analyses confined to 229 Hispanic youthIndividual factors (covariates)nReduced multivariable modelabeta +/- SEPpOR95% CIHIV-1 infection169-0.83 +/- 0.21<0.00010.190.08-0.43Individual HLA variantsb DRB1*0804111.26 +/- 0.630.0453.531.03-12.06 DRB1*15470.77 +/- 0.330.0192.161.13-4.10aFollowing similar strategies shown in Table 4, except that (i) status of HIV-1 infection replaces CD4+ T cell count as the primary non-genetic factor; (ii) only age and sex are treated as additional covariatesbOther HLA variants, including DRB1*03 and DRB1*0701, are dismissed (adjusted P > 0.050)
###end p 56
###begin p 57
Multivariable analyses confined to 229 Hispanic youth
###end p 57
###begin p 58
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 74 79 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
aFollowing similar strategies shown in Table 4, except that (i) status of HIV-1 infection replaces CD4+ T cell count as the primary non-genetic factor; (ii) only age and sex are treated as additional covariates
###end p 58
###begin p 59
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
bOther HLA variants, including DRB1*03 and DRB1*0701, are dismissed (adjusted P > 0.050)
###end p 59
###begin title 60
Secondary analyses of SNPs
###end title 60
###begin p 61
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2007</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2007</xref>
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2007</xref>
###xml 338 342 338 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2009</xref>
###xml 580 581 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 663 664 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1170 1174 1169 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 1383 1384 1382 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1617 1623 1616 1622 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1647 1648 1646 1647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1820 1821 1819 1820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1887 1891 1886 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 1893 1898 1892 1897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-C</italic>
###xml 1904 1909 1903 1908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNRD1</italic>
###xml 2006 2007 2005 2006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2028 2031 2027 2030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 2033 2036 2032 2035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LTA</italic>
###xml 2042 2045 2041 2044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LTB</italic>
###xml 2145 2146 2140 2141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2188 2196 2183 2191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 2199 2203 2194 2198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 2210 2214 2205 2209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 2228 2229 2223 2224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2662 2666 2657 2661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 2694 2695 2689 2690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1623 2704 1622 2699 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="62">Distribution of nominal <italic>P</italic> values in the analyses of 88 single nucleotide polymorphisms (SNPs) within three regions of the human major histocompatibility complex (MHC) (Table S2). MHC class I SNPs (<italic>n</italic>&#160;=&#160;62) are mapped to HLA class I and neighboring genes, including <italic>HCP5</italic>, <italic>HLA-C</italic>, and <italic>ZNRD1</italic> previously associated with HIV-1-related outcomes (see text). MHC class III (central MHC) SNPs (<italic>n</italic>&#160;=&#160;14) are mapped to <italic>TNF</italic>, <italic>LTA</italic>, and <italic>LTB</italic>, which encode TNF-&#945;, lymphotoxic alpha, and lymphotoxic beta, respectively. MHC class II SNPs (<italic>n</italic>&#160;=&#160;12) are in non-coding sequences around <italic>HLA-DRB1</italic>, -<italic>DQA1</italic>, and -<italic>DQB1</italic>. The nominal <italic>P</italic> values are based on Chi-square tests of non-responders (serum antibody concentrations &lt;10&#160;mIU/mL at week 28), responders (10&#8211;1,000&#160;mIU/mL), and high responders (&gt;1,000&#160;mIU/mL). All SNPs are sorted by their relative order (from telomere to centromere) instead of actual distance on the short arm of chromosome 6. For clarity, three spaces are introduced between MHC blocks. Only a single SNP (rs2523685) in the 5&#8242; flanking region of <italic>HCP5</italic> has trend for association (<italic>P</italic>&#160;=&#160;0.021)</p>
###xml 1623 2704 1622 2699 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="62">Distribution of nominal <italic>P</italic> values in the analyses of 88 single nucleotide polymorphisms (SNPs) within three regions of the human major histocompatibility complex (MHC) (Table S2). MHC class I SNPs (<italic>n</italic>&#160;=&#160;62) are mapped to HLA class I and neighboring genes, including <italic>HCP5</italic>, <italic>HLA-C</italic>, and <italic>ZNRD1</italic> previously associated with HIV-1-related outcomes (see text). MHC class III (central MHC) SNPs (<italic>n</italic>&#160;=&#160;14) are mapped to <italic>TNF</italic>, <italic>LTA</italic>, and <italic>LTB</italic>, which encode TNF-&#945;, lymphotoxic alpha, and lymphotoxic beta, respectively. MHC class II SNPs (<italic>n</italic>&#160;=&#160;12) are in non-coding sequences around <italic>HLA-DRB1</italic>, -<italic>DQA1</italic>, and -<italic>DQB1</italic>. The nominal <italic>P</italic> values are based on Chi-square tests of non-responders (serum antibody concentrations &lt;10&#160;mIU/mL at week 28), responders (10&#8211;1,000&#160;mIU/mL), and high responders (&gt;1,000&#160;mIU/mL). All SNPs are sorted by their relative order (from telomere to centromere) instead of actual distance on the short arm of chromosome 6. For clarity, three spaces are introduced between MHC blocks. Only a single SNP (rs2523685) in the 5&#8242; flanking region of <italic>HCP5</italic> has trend for association (<italic>P</italic>&#160;=&#160;0.021)</p></caption>
###xml 2704 2704 2699 2699 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="439_2009_720_Fig1_HTML" id="MO1"/>
###xml 1617 2704 1616 2699 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="62">Distribution of nominal <italic>P</italic> values in the analyses of 88 single nucleotide polymorphisms (SNPs) within three regions of the human major histocompatibility complex (MHC) (Table S2). MHC class I SNPs (<italic>n</italic>&#160;=&#160;62) are mapped to HLA class I and neighboring genes, including <italic>HCP5</italic>, <italic>HLA-C</italic>, and <italic>ZNRD1</italic> previously associated with HIV-1-related outcomes (see text). MHC class III (central MHC) SNPs (<italic>n</italic>&#160;=&#160;14) are mapped to <italic>TNF</italic>, <italic>LTA</italic>, and <italic>LTB</italic>, which encode TNF-&#945;, lymphotoxic alpha, and lymphotoxic beta, respectively. MHC class II SNPs (<italic>n</italic>&#160;=&#160;12) are in non-coding sequences around <italic>HLA-DRB1</italic>, -<italic>DQA1</italic>, and -<italic>DQB1</italic>. The nominal <italic>P</italic> values are based on Chi-square tests of non-responders (serum antibody concentrations &lt;10&#160;mIU/mL at week 28), responders (10&#8211;1,000&#160;mIU/mL), and high responders (&gt;1,000&#160;mIU/mL). All SNPs are sorted by their relative order (from telomere to centromere) instead of actual distance on the short arm of chromosome 6. For clarity, three spaces are introduced between MHC blocks. Only a single SNP (rs2523685) in the 5&#8242; flanking region of <italic>HCP5</italic> has trend for association (<italic>P</italic>&#160;=&#160;0.021)</p></caption><graphic position="anchor" xlink:href="439_2009_720_Fig1_HTML" id="MO1"/></fig>
###xml 387 392 <span type="species:ncbi:9606">human</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 1745 1750 <span type="species:ncbi:9606">human</span>
###xml 1937 1942 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Secondary analyses tested the hypothesis that non-coding SNPs in and around HLA class II genes might also be contributory, because of their potential influence on gene expression and/or mRNA splicing, as implied by genome-wide association studies (Dalmasso et al. 2008; Fellay et al. 2007; Hafler et al. 2007; Kuniholm 2007; Limou et al. 2009). A panel of 88 SNPs within three blocks of human MHC was successfully genotyped in 280 patients with at least 2 mug of high-quality DNA at the completion of HLA genotyping. One SNP (rs2523685) mapped to MHC class I region had a nominal P value at 0.021 in test of SNP genotypes among the three Ab response groups (Fig. 1). This weak association was driven by the heterozygous genotype (rs2523685CG), which was present in 31 (37.8%) out of 82 HR, 70 (49.3%) out of 142 MR, and 33 (58.9%) out of 56 NR patients. Homozygosity for the minor allele (genotype GG) had no trend (24.4% HR, 14.1% MR, and 21.4% NR). The putative association of rs2523685 genotypes with differential Ab responses could be dismissed for three reasons. First, the rs2523685 SNP is mapped to the 5' flanking region (distant from the promoter sequences) of HCP5 (Table S2), without any predicted or known functional relevance for either allele. Second, likelihood of chance association was high-about two random associations were expected from the tests of 88 SNPs when P value was accepted at 0.021. Alternatively, 1.3 random associations were expected from the tests of 62 MHC class I SNPs alone. Third, the SNP is remote from the HLA class II genes that produced the strongest signals in all analyses.Fig. 1Distribution of nominal P values in the analyses of 88 single nucleotide polymorphisms (SNPs) within three regions of the human major histocompatibility complex (MHC) (Table S2). MHC class I SNPs (n = 62) are mapped to HLA class I and neighboring genes, including HCP5, HLA-C, and ZNRD1 previously associated with HIV-1-related outcomes (see text). MHC class III (central MHC) SNPs (n = 14) are mapped to TNF, LTA, and LTB, which encode TNF-alpha, lymphotoxic alpha, and lymphotoxic beta, respectively. MHC class II SNPs (n = 12) are in non-coding sequences around HLA-DRB1, -DQA1, and -DQB1. The nominal P values are based on Chi-square tests of non-responders (serum antibody concentrations <10 mIU/mL at week 28), responders (10-1,000 mIU/mL), and high responders (>1,000 mIU/mL). All SNPs are sorted by their relative order (from telomere to centromere) instead of actual distance on the short arm of chromosome 6. For clarity, three spaces are introduced between MHC blocks. Only a single SNP (rs2523685) in the 5' flanking region of HCP5 has trend for association (P = 0.021)
###end p 61
###begin p 62
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-C</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNRD1</italic>
###xml 383 384 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 405 408 405 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 410 413 410 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LTA</italic>
###xml 419 422 419 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LTB</italic>
###xml 522 523 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 565 573 561 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 576 580 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 587 591 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 605 606 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1039 1043 1035 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 1071 1072 1067 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 314 319 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distribution of nominal P values in the analyses of 88 single nucleotide polymorphisms (SNPs) within three regions of the human major histocompatibility complex (MHC) (Table S2). MHC class I SNPs (n = 62) are mapped to HLA class I and neighboring genes, including HCP5, HLA-C, and ZNRD1 previously associated with HIV-1-related outcomes (see text). MHC class III (central MHC) SNPs (n = 14) are mapped to TNF, LTA, and LTB, which encode TNF-alpha, lymphotoxic alpha, and lymphotoxic beta, respectively. MHC class II SNPs (n = 12) are in non-coding sequences around HLA-DRB1, -DQA1, and -DQB1. The nominal P values are based on Chi-square tests of non-responders (serum antibody concentrations <10 mIU/mL at week 28), responders (10-1,000 mIU/mL), and high responders (>1,000 mIU/mL). All SNPs are sorted by their relative order (from telomere to centromere) instead of actual distance on the short arm of chromosome 6. For clarity, three spaces are introduced between MHC blocks. Only a single SNP (rs2523685) in the 5' flanking region of HCP5 has trend for association (P = 0.021)
###end p 62
###begin title 63
Discussion
###end title 63
###begin p 64
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1993</xref>
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">1998</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1986</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1993</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1992</xref>
###xml 350 354 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1998</xref>
###xml 356 361 356 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2002b</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1988</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">1995</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">1997</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">1997</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2002</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">1988</xref>
###xml 523 527 523 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">1988</xref>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 704 708 704 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1998</xref>
###xml 948 952 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2003</xref>
###xml 1135 1139 1135 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1993</xref>
###xml 1155 1159 1155 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1998</xref>
###xml 1179 1183 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">1995</xref>
###xml 1185 1189 1185 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2000</xref>
###xml 1208 1212 1208 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">1997</xref>
###xml 1227 1231 1227 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">1997</xref>
###xml 1251 1255 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">1995</xref>
###xml 133 136 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 182 188 <span type="species:ncbi:9606">infant</span>
###xml 581 584 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 722 730 <span type="species:ncbi:9606">patients</span>
###xml 744 747 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 881 889 <span type="species:ncbi:9606">patients</span>
###xml 915 918 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Our analyses of three HLA class II genes in 335 youth confirmed the negative impact of DRB1*03 and DRB1*0701 on peak Ab responses to HBV vaccination, as reported in prior studies of infant, adolescent, and adult populations (Belloni et al. 1993; Caillat-Zucman et al. 1998; Craven et al. 1986; del Canho et al. 1993; Hatae et al. 1992; Hohler et al. 1998, 2002b; Kramer et al. 1988; Martinetti et al. 1995; McDermott et al. 1997; Peces et al. 1997; Qian et al. 2002; Wang et al. 2004; Watanabe et al. 1988; Weissman et al. 1988). Although our study relied heavily on Hispanics and HIV+ youth, the main findings most closely resembled those reported earlier for adults of European ancestry (Hohler et al. 1998). Studies on patients with natural HBV infection lend further support for these immunogenetic findings, as HLA haplotypes having either DRB1*03 or DRB1*07 were enriched in patients who were unable to clear HBV after infection (Thio et al. 2003). In addition, as both DRB1*03 and DRB1*0701 are in strong LD with DQB1*02 (DQ2 by serology), their relationships to Ab responses were partially reflected by DQB1*02 (Belloni et al. 1993; Hohler et al. 1998; Martinetti et al. 1995, 2000; McDermott et al. 1997; Peces et al. 1997; Stachowski et al. 1995).
###end p 64
###begin p 65
###xml 191 199 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 425 433 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1</italic>
###xml 439 443 439 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 487 495 487 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 814 818 814 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1993</xref>
###xml 834 838 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1998</xref>
###xml 1299 1303 1299 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2006</xref>
###xml 1468 1469 1468 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1672 1673 1672 1673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 700 703 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 772 779 <span type="species:ncbi:9606">infants</span>
In population-based analyses of diverse HLA alleles, statistical power (sample size and allele frequency), false discoveries, and population heterogeneity are some of the major concerns. The HLA-DRB1 variants negatively associated with Ab responses were relatively common in our study population, but statistical power alone could not account for these key findings because statistical power actually favored the analyses of HLA-DQA1 and -DQB1 variants, which are much less diverse than HLA-DRB1 alleles. False discovery was also unlikely because various studies have led to similar conclusions. Indeed, even the minor finding on DRB1*15 (DR2 by serology), which appeared to be a favorable factor in HIV+ youth (Table 4), was also consistent with evidence from studies of infants and adults (Caillat-Zucman et al. 1993; Hohler et al. 1998). Population heterogeneity, on the other hand, could obscure causal relationships when analyses can only survey tagging variants instead of the functional units. However, heterogeneity in ethnic backgrounds could not compromise our major findings at least for three reasons. First, individual HLA alleles encode structurally and functionally distinct protein products that facilitate immune surveillance regardless of racial or ethnic background (Jones et al. 2006). Second, parameter estimates for DRB1*03 and DRB1*0701 were mostly insensitive to statistical adjustments for non-genetic factors, including race/ethnicity (Table 2). Third, our analyses dismissed the potential confounding by other genetic variants, especially those (e.g., DQB1*0201 and DQB1*0202) that are known to be in strong LD with DRB1*03 and DRB1*0701 (Table 2).
###end p 65
###begin p 66
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2004</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2006</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2004</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2006</xref>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 440 443 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 633 636 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 788 791 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1050 1053 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1163 1166 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HLA class II alleles have been associated with differential Ab responses to other vaccines, including measles-mumps-rubella (MMR) vaccine (Ovsyannikova et al. 2004, 2006). In US schoolchildren (mostly European Americans) who received MMR vaccination, DRB1*08 was considered unfavorable-being negatively associated with desirable immune response (Ovsyannikova et al. 2004), which contrasted with its positive association with Ab response to HBV vaccination here. Another study reported a disadvantage for DRB1*0801 in primary biliary cirrhosis patients of European descent (Donaldson et al. 2006). While predominance of Hispanics and HIV+ subjects in our study population might be one of the reasons for seemingly inconsistent findings between studies, MMR vaccine is quite different from HBV vaccine in that it uses attenuated viruses instead of recombinant antigens. Moreover, DRB1*08 in our study population was represented by at least three common alleles (DRB1*0801, *0802, and *0804) and only DRB1*0804 had the clearest impact on Ab response to HBV vaccine (Table S2). In the absence of highly comparable data from other studies, the relevance of DRB1*08 to HBV vaccination deserves further evaluation in larger populations.
###end p 66
###begin p 67
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2006</xref>
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2008</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2005</xref>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2008</xref>
###xml 566 570 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2007</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2009</xref>
###xml 627 631 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2009</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">2009</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2008</xref>
###xml 1031 1035 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2004</xref>
###xml 1053 1057 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">2003</xref>
###xml 1217 1218 1217 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1473 1477 1473 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">2004</xref>
###xml 1620 1621 1620 1621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1764 1768 1764 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 486 491 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 995 1000 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1109 1112 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1128 1136 <span type="species:ncbi:9606">patients</span>
###xml 1438 1443 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1617 1620 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In contrast to HLA alleles with well-defined function, the MHC SNPs are mostly within non-coding sequences and are suitable for testing secondary hypotheses about relevance of gene expression and tagging of other HLA alleles (de Bakker et al. 2006; Listgarten et al. 2008; Miretti et al. 2005) not specifically captured in routine HLA genotyping. Our selection of SNPs in MHC class I region was dictated by recent studies, which have demonstrated the potential influence of MHC SNPs on HIV-1 pathogenesis and disease progression (Catano et al. 2008; Dalmasso et al. 2008; Fellay et al. 2007; Limou et al. 2009; Shrestha et al. 2009; van Manen et al. 2009). Although multiple SNPs can tag a few HLA class I alleles (e.g., B*5701) and serology groups (e.g., A10), these SNPs had little overlap with the panel of SNPs that can be used to reliably infer HLA class I alleles (Listgarten et al. 2008). The critical role of protective HLA class I alleles (e.g., B*5701 and B*5703) in immune control of HIV-1 infection (O'Brien and Nelson 2004; Tang and Kaslow 2003) was expected to indirectly benefit Ab response to HBV vaccination if patients are not receiving antiretroviral therapy. In analyses of MHC class I SNPs (Fig. 1), the absence of any apparent association was somewhat consistent with the earlier observation that HLA class I alleles and haplotypes were not associated with Ab responses in the REACH cohort (also consisted mostly of HIV-1-infected youth) (Wang et al. 2004). The new study population assembled here was not suitable for testing the indirect effects produced by HLA class I genotypes, because few HIV+ youth (less than 10%) had severe immunodeficiency at the time of vaccination. The weak signal produced by a single, non-coding SNP within the HCP5 gene is probably worth pursuing in larger, homogeneous cohorts, as analyses of SNPs without well-established functional attributes typically require stratification by race.
###end p 67
###begin p 68
###xml 235 243 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2006</xref>
###xml 811 815 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2005</xref>
###xml 1037 1045 1037 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 1067 1072 1067 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2002a</xref>
###xml 138 141 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
In summary, both primary and secondary analyses of HLA and related genotypes have reiterated multifactorial influences on Ab responses to HBV vaccination in youth. Recognition of immunodeficiency (the loss of CD4+ T cells) and several HLA-DRB1 alleles as independent predictors of Ab response highlights the importance of T-helper cell-dependent pathways and HLA class II antigen presentation to effective vaccination using recombinant antigens. This work has also paved the way for further high-throughput SNP typing that may reveal additional factors, including regulatory (non-coding) sequence variations commonly found in immune response genes beyond the HLA region, as well as coding sequence variations that are also common in genes encoding killer immunoglobulin receptors (Bashirova et al. 2006; Parham 2005). Systematic evaluation of non-HLA genes can be informative, as studies of European twins have already indicated that almost 59% of heritability in Ab responses to HBsAg can be attributed to genetic variations beyond the HLA-DRB1 locus (Hohler et al. 2002a).
###end p 68
###begin p 69
Below is the link to the electronic supplementary material.
###end p 69
###begin p 70
Supplementary material 1 (DOC 282 kb)
###end p 70
###begin p 71
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 188 193 <span type="species:ncbi:9606">Child</span>
###xml 205 210 <span type="species:ncbi:9606">Human</span>
This work was supported by the Adolescent Trials Network for HIV/AIDS Interventions (ATN), with primary funding through two grants (U01 HD40474 and U01 HD40533) from National Institute of Child Health and Human Development (B. Kapogiannis, L. Serchuck) and supplemental funding from the National Institute of Allergy and Infectious Diseases (Patrick Jean-Philippe), National Institute on Drug Abuse (N. Borek), as well as National Institute of Mental Health (P. Brouwers, S. Allison). J.T. is the recipient of an independent scientist award (K02 AI076123) from National Institute of Allergy and Infectious Diseases. The entire project was scientifically reviewed by ATN's Therapeutic Leadership Group. Network, scientific and logistical support was provided by the ATN Coordinating Center (C. Wilson, C. Partlow) at the University of Alabama at Birmingham. Network operations and analytic support came from the ATN Data and Operations Center at Westat Inc. (J. Korelitz, B. Driver). We sincerely thank members of the local youth Community Advisory Boards for their insight and counsel, the youth who participated in this study for their cooperation, Stephanie Crane (Adolescent Medicine Trials Unit) and Jenese Tucker (Westat) for valuable assistance with protocol implementation, Rick Mitchell (Westat) for data management, Richard A. Kaslow, Audrey Rogers, and Steven Spector for consultation and advice on protocol development, Karine Viaud (Illumina) for assistance with bioinformatics, Dale Isabelle and Mary Shirley for administrative assistance, Peter Havens, Sharon Nachman, Bret Rudy, Kathleen Squires, and John Sleasman for critical reading of an earlier version of this manuscript.
###end p 71
###begin p 72
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 72
###begin title 73
Appendix
###end title 73
###begin p 74
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 1148 1156 <span type="species:ncbi:9606">Children</span>
###xml 1507 1515 <span type="species:ncbi:9606">Children</span>
###xml 1620 1628 <span type="species:ncbi:9606">Children</span>
###xml 1737 1745 <span type="species:ncbi:9606">Children</span>
###xml 2549 2557 <span type="species:ncbi:9606">Children</span>
###xml 2709 2717 <span type="species:ncbi:9606">Children</span>
This study (designated as ATN 052) also involved additional investigators and staff who enrolled patients at 22 clinical sites, including University of Maryland (Ligia Peralta, MD, Esther Collinetti, BA, Leonel Flores, MD, Reshma S. Gorle); Hospital dos Servidores do Estado, Rio de Janeiro (Esau C. Joao, MD, Leticia S. Cruz, MD, Eduarda Gusmao, MD, Angela B. N. Carvalho, MD); Universidade Federale de Minas Gerais, Minas Gerais (Jorge Pinto, MD, Flavia G. F. Ferreira, MD); St. Jude Research Hospital (Sarah Stender, MD, Kristen Branum, BS, Tina Culley, BS, RHIA, CCRP, Carla McKinley, RN, MSN, Thomas Wride, MS); Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto-Universidade de Sao Paulo, Sao Paulo (Geraldo Duarte, MD, Marisa M. M. Pinhata, MD, Carolina S. Vieira, MD); Instituto de Puericultura e Pediatria Martagao Geseteira, Rio de Janeiro (Ricardo H. S. Oliveira, MD, Maria C. C. Sapia, MD, Thalita F. Abreu, MD); Instituteo de Infectologia Emilio Ribas Sao Paulo (Marinella D. Negra, MD, Wladimir Queiroz, MD); Montefiore Medical Center (Donna Futterman, MD, Elizabeth Enriquez-Bruce, MD, Maria Campos, RN); Harriet Shezi Children's Clinic, Johannesburg (Tammy Meyers, MD, Lee Kleynhans, MD, Megan Palmer, MD, Angela Oosthuizen, BS); John H. Stroger Jr. Hospital of Cook County and the CORE Center (Jaime Martinez, MD, Lisa Henry-Reid, Kelly Bojan, Rachel Jackson, MSN, APN, CFNP); University of Puerto Rico, Puerto Rico (Irma L. Febo, MD, Hazel T Ayala-Flores, Anne T. F. Gomez); Children's Diagnostic and Treatment Center (Ana Puga, MD, Lisa Bridges, RN, Amy Inman, BS, Esmine Leonard, BSN); Children's National Cancer Center (Lawrence J. D'Angelo, MD, Connie Trexler, RN, Rita Hagler, BA, Amy Klamberg, BA); Children's Hospital of Los Angeles (Marvin Belzer, MD, Mirna Sweeney, RN, Diane Tucker, RN, MSN); Tulane University Health Sciences Center (Sue Ellen Abdalian, MD, Leslie Kozina, RN, CCRC, Alyne Baker, RN, MN, Trina Jeanjacques, BA); University of California at San Diego (Steven Spector, MD, Ronaldo M. Viani, MD, Jean M. Manning, BSN, Kim A. Norris, BSN, Lisa Stangl, PNP); University of South Florida (Patricia Emmanual, MD, Jorge Lujan-Zilbermann, MD, Diane M. Straub, MD, Silvia Callejas, BSN, ACRN, Priscilla C. Julian, RN, Amayvis Rebolledo, MAD); University of California at San Francisco (Babara Moscicki, MD, Coco Auerswald, MD, Lisa D. Irish, BSN, J. B. Molaghan, BA); Mount Sinai Medical Center (John B. Steever, MD, Angela Diaz, MD, Henry Sacks, MD, Mary S. Geiger, RN, MPH, Angela Lee, PA-C, MPH); Children's Hospital of Boston (Cathryn Samples, MD, Brian Abascal, MFA, BA); Duke University (John Swetnam, MEd, Felicia Wiley, RN, Kareema Whitfield); Alabama Children's Hospital (Robert Pass, MD, Heather Charlton, BSN, Beatty Newana, BA); San Juan City Hospital (Midnela Acevedo, MD, Milagros Gonzalez, MD, Lourdes Angeli, RN, MPH, Wanda Marrero, RN, Elvia Perez, MEd, MA).
###end p 74
###begin title 75
References
###end title 75
###begin article-title 76
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genetic variation studies and HLA class II loci
###end article-title 76
###begin article-title 77
The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense
###end article-title 77
###begin article-title 78
Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers
###end article-title 78
###begin article-title 79
Phylogenetic history of hominoid DRB loci and alleles inferred from intron sequences
###end article-title 79
###begin article-title 80
###xml 74 82 <span type="species:ncbi:9606">patients</span>
HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients
###end article-title 80
###begin article-title 81
Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen
###end article-title 81
###begin article-title 82
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNRD1</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-C</italic>
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-A10</italic>
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-B*57</italic>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles
###end article-title 82
###begin article-title 83
###xml 12 40 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination
###end article-title 83
###begin article-title 84
###xml 23 40 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years
###end article-title 84
###begin article-title 85
###xml 31 48 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses
###end article-title 85
###begin article-title 86
Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings
###end article-title 86
###begin article-title 87
###xml 96 99 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients
###end article-title 87
###begin article-title 88
###xml 23 40 <span type="species:ncbi:10407">hepatitis B virus</span>
Global epidemiology of hepatitis B virus
###end article-title 88
###begin article-title 89
###xml 37 40 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study
###end article-title 89
###begin article-title 90
###xml 92 97 <span type="species:ncbi:9606">human</span>
A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC
###end article-title 90
###begin article-title 91
###xml 105 108 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients
###end article-title 91
###begin article-title 92
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leucocyte antigens (HLA) in neonates with an inadequate response to hepatitis B vaccination
###end article-title 92
###begin article-title 93
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus infection
###end article-title 93
###begin article-title 94
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study
###end article-title 94
###begin article-title 95
Conserved extended haplotypes of the major histocompatibility complex: further characterization
###end article-title 95
###begin article-title 96
Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors
###end article-title 96
###begin article-title 97
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A whole-genome association study of major determinants for host control of HIV-1
###end article-title 97
###begin article-title 98
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose
###end article-title 98
###begin article-title 99
Risk alleles for multiple sclerosis identified by a genomewide study
###end article-title 99
###begin article-title 100
###xml 40 57 <span type="species:ncbi:10407">hepatitis B virus</span>
Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype
###end article-title 100
###begin article-title 101
###xml 108 113 <span type="species:ncbi:9606">human</span>
###xml 118 128 <span type="species:ncbi:9598">chimpanzee</span>
Recent divergence of the HLA-DRB1*04 allelic lineage from the DRB1*0701 lineage after the separation of the human and chimpanzee species
###end article-title 101
###begin article-title 102
The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg
###end article-title 102
###begin article-title 103
###xml 98 115 <span type="species:ncbi:12092">hepatitis A virus</span>
Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins
###end article-title 103
###begin article-title 104
C4A deficiency and nonresponse to hepatitis B vaccination
###end article-title 104
###begin article-title 105
MHC class II proteins and disease: a structural perspective
###end article-title 105
###begin article-title 106
Non-responsiveness to hepatitis-B vaccination: revaccination and immunogenetic typing
###end article-title 106
###begin article-title 107
Replicating genome-wide association studies
###end article-title 107
###begin article-title 108
Chronic hepatitis B-new goals, new treatment
###end article-title 108
###begin article-title 109
Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02)
###end article-title 109
###begin article-title 110
Statistical resolution of ambiguous HLA typing data
###end article-title 110
###begin article-title 111
###xml 5 8 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Anti-HBV neonatal immunization with recombinant vaccine. Part II. Molecular basis of the impaired alloreactivity
###end article-title 111
###begin article-title 112
###xml 32 49 <span type="species:ncbi:10407">hepatitis B virus</span>
Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond
###end article-title 112
###begin article-title 113
###xml 16 21 <span type="species:ncbi:9606">human</span>
Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination
###end article-title 113
###begin article-title 114
###xml 81 84 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection
###end article-title 114
###begin article-title 115
###xml 52 57 <span type="species:ncbi:9606">human</span>
A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms
###end article-title 115
###begin article-title 116
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genes that limit AIDS
###end article-title 116
###begin article-title 117
###xml 21 26 <span type="species:ncbi:9606">human</span>
Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination
###end article-title 117
###begin article-title 118
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine
###end article-title 118
###begin article-title 119
###xml 30 35 <span type="species:ncbi:9606">human</span>
Influence of KIR diversity on human immunity
###end article-title 119
###begin article-title 120
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 83 100 <span type="species:ncbi:10407">Hepatitis B virus</span>
Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
###end article-title 120
###begin article-title 121
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients
###end article-title 121
###begin article-title 122
Association of immune response to hepatitis B vaccine with HLA-DRB1*02, 07, 09 genes in the population of Han nationality in Guangdong Province
###end article-title 122
###begin article-title 123
###xml 91 94 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 125 130 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load
###end article-title 123
###begin article-title 124
The IMGT/HLA and IPD databases
###end article-title 124
###begin article-title 125
###xml 96 113 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 131 134 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection
###end article-title 125
###begin article-title 126
HLA dictionary 2004: summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens
###end article-title 126
###begin article-title 127
###xml 20 25 <span type="species:ncbi:9606">human</span>
Molecular typing of human leukocyte antigen and related polymorphisms following whole genome amplification
###end article-title 127
###begin article-title 128
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Host genetics and HIV-1 viral set-point in African Americans
###end article-title 128
###begin article-title 129
###xml 39 56 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients
###end article-title 129
###begin article-title 130
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy
###end article-title 130
###begin article-title 131
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 118 153 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
HLA-DRB1 and -DQB1 alleles and haplotypes in Zambian couples and their associations with heterosexual transmission of human immunodeficiency virus type 1
###end article-title 131
###begin article-title 132
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 70 73 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples
###end article-title 132
###begin article-title 133
###xml 72 89 <span type="species:ncbi:10407">hepatitis B virus</span>
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection
###end article-title 133
###begin article-title 134
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-C</italic>
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCP5</italic>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection
###end article-title 134
###begin article-title 135
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination
###end article-title 135
###begin article-title 136
###xml 86 92 <span type="species:ncbi:9606">humans</span>
Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells
###end article-title 136
###begin article-title 137
Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine
###end article-title 137
###begin article-title 138
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health
###end article-title 138
###begin article-title 139
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 57 65 <span type="species:ncbi:9606">children</span>
Impaired response to hepatitis B vaccine in HIV infected children
###end article-title 139
###begin p 140
###xml 47 50 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
For the Adolescent Medicine Trials Network for HIV/AIDS Interventions.
###end p 140
###begin p 141
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 141
###begin p 142
The online version of this article (doi:10.1007/s00439-009-0720-z) contains supplementary material, which is available to authorized users.
###end p 142

